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ABSTRACT 
 
DEVELOPMENT OF PRE-CLINICAL ASSAYS BASED ON TANDEM MASS SPECTROMETRY TO 
INVESTIGATE GABAA RECEPTOR MODULATORS 
 
 by  
 
Margaret L. Guthrie 
 
The University of Wisconsin – Milwaukee, 2017 
Under the Supervision of Professor Alexander (Leggy) Arnold 
 
 
 
  Drugs are compounds that interact with a biological system to produce a specific 
biological response. The goal of drug discovery is to design and synthesize a pharmaceutical 
agent that will produce a desired biological effect. However, the in-vivo effects of a drug 
molecule cannot be predicted without a variety of test results prior to human clinical trials. In 
order to designate any drug compound as a leading candidate (or “lead” compound), it needs 
to show significant pharmacological activity, maintain a desirable metabolic half-life, and 
display minimal side effects and toxicity.  Several in-vitro and in-vivo pre-clinical assays have 
been developed to measure metabolic parameters and aim to qualify, or rule out, compounds 
based on drug distribution within the body.  The developments of these assays are presented 
herein.           
First, an assay was developed to estimate metabolic half-life of drug compounds in vitro 
using human and mouse liver microsomes by liquid chromatography-mass spectrometry (LC-
MS).  Secondly, a method for determination of pharmacokinetic (PK) parameters was 
developed and optimized using absolute quantitation by LC-MS/MS.  Thirdly, metabolic stability 
was further estimated in cell suspensions and tissue homogenates, specifically using HepG2 
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cells as a model for hepatocytes, and rat brain as a model for illustrating stereochemical 
specificity within the brain enzymatic metabolism.  Finally, to visualize the spatial distribution of 
small molecules in-vivo, matrix assisted laser desorption ionization tandem mass spectrometry 
(MALDI-MS/MS) was employed to image the distribution of drug compounds in whole tissue 
slices. By employing a variety of mass spectrometric techniques, we have been able to both 
assess the viability and follow the distribution of lead compounds from in-vitro sub-cellular 
fractions to whole cells through whole tissues and carry out in-vivo studies. 
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CHAPTER 1. INTRODUCTION 
1.1 Introduction to Drug Discovery  
The successful introduction of a new therapeutic treatment into the marketplace is a 
time consuming and expensive endeavor, one which is estimated to take more than 8 years and 
$500 million dollars.2 Before a novel treatment can reach clinical trials, it must withstand a 
myriad of pre-clinical assays, and show efficacy to treat the disease, display selectivity to the 
intended target molecule or target organ, and yield limited adverse side effects. The ability to 
exclude underperforming lead compounds in a high throughput and cost effective manner is 
crucial to the field of drug discovery. The development of a new pharmaceutical product occurs 
in several stages. Some general stages include target identification, drug compound discovery, 
investigational new drug application, clinical trials, and commercialization. Firstly, the biological 
target mediating the disease must be verified. This can be a protein target, such as an enzyme 
or receptor, or a nucleic acid target, such as DNA. The drug discovery process then moves to the 
identification of an initial lead compound, which has been identified as a promising candidate 
to treat the disease by way of acting at the established drug target. Usually this strategy 
involves a high throughput screening method or rational drug design. Typically, the initial lead 
compound will require structural modifications to improve binding, reduce adverse side effects, 
and to produce the maximum desired pharmacological effect. Changes in the structure of a 
drug compound, as well as changes to the method of administration (oral dosing, inhalation, or 
injection), will impact the biological effects to the test subject. The assays presented herein are 
designed to aid in the drug discovery process after an initial lead has been identified, by 
measuring parameters that impact important drug properties. A general outline for the drug 
discovery and development process is presented in Figure 1.   
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The study of how a drug is absorbed, distributed, metabolized and excreted (generally 
abbreviated as ADME) is a vast field in drug discovery as it characterizes important drug-like 
properties of a lead compound.1 The term ‘ADMET’ is often used as well to describe toxicity in 
addition to the other terms, which is an important consideration because drugs that are not 
undeniably safe will not become commercial drugs. It is important to understand the 
movement of a drug within the body and how the body processes a drug. In this work, assays 
are presented using mice to ascertain such information. However, before a compound can 
advance to in vivo experiments with animals, it should be characterized by inexpensive, rapid, 
efficient and high-throughput in vitro assays. These assays are presented first and foremost in 
the upcoming chapters.  
 
Figure 1. General outline of the drug discovery process from target inception to market.3 
Eliminate 
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Both in vitro and in vivo assays have been developed by the Arnold Group embedded in 
the Milwaukee Institute for Drug Discovery to characterize synthesized drug candidates at 
UWM and in collaboration with other universities and companies. The goal of these 
collaborative projects is to move a lead compound forward into clinical trials, ideally creating a 
novel treatment for a selected disease target (such as asthma, cancer, neuropathic pain, 
depression, and many others). The assays assist medicinal chemists within the MIDD to 
determine if structural modifications can be made to lead compounds to increase desirable 
drug-like properties of the molecule. These properties include bioavailability, metabolic 
stability, and absence of toxicity.  Figure 2 illustrates characteristics of drug compounds that 
should be optimized, as well as characteristics that should be avoided when designing a new 
drug. The assays developed herein have kept these properties in mind and aim to answer 
questions regarding these characteristics. 
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Figure 2. Criteria for optimization of lead compounds in drug development.4 
There are some general guidelines that medicinal chemists follow to aid in improving a 
drug candidate with regard to the above criteria. One such guideline is Lipinski’s Rules of Five.5  
These rules include avoiding molecules with more than five hydrogen bond donors, molecular 
weights over 500,  octanol-water partition coefficients (logPo/w) greater than five, or a sum of 
nitrogen and oxygen atoms (within the molecule) above ten. Typically molecules that do not 
obey these general rules will display poor ADME properties.5-6 It is important for a drug 
candidate to display optimum ADME characteristics, as compounds that are not stable in the 
body (whether they are excreted too quickly or readily metabolized into other compounds) may 
not have the desired pharmaceutical effects.  Not only must a compound be stable upon 
entering the body, it also must be relocated to its target tissue after absorption into the 
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bloodstream. For example, in our pursuit to treat asthma, it is important to verify that the 
compound reaches the lung, as it is the target organ. Drug distribution refers to the relocation 
of the drug from blood to the various tissues in the body, and the rate at which it occurs is an 
important ADME property.7   
Once the drug has been distributed to the target location, the body will clear the drug 
by two general pathways; metabolism and excretion. Understanding the metabolism of highly 
lipophilic molecules is important, because these molecules will typically undergo 
biotransformation into a readily excreted polar metabolite.8  Many xenobiotics, or compounds 
that are exogenous to the body, are cleared this way.  Large lipophilic molecules will be 
converted to more water-soluble products before renal elimination.  The liver will also 
participate in the excretion process via the bile duct.7  In vitro assays can be conducted to 
estimate the uptake of a compound into cells (for example, in hepatic cells), but this does not 
necessarily equate directly to excretion, as there are many processes that occur after a drug has 
been taken up into a cell.9 Therefore, renal and fecal excretions are studied in vivo because in 
vitro assays do not emulate these processes well.6 For this reason, the excretion portion of 
ADME has not been extensively studied in this work. 
1.2 Drug Target: GABAA Receptor 
The molecular target that has been identified for all lead compounds tested herein is 
the GABAA receptor (GABAAR). GABA (1,4-aminobutanoic acid, or γ-aminobutryic acid) is the 
major inhibitory neurotransmitter in the brain that influences neurons via a large number of 
receptors, which are grouped based on their pharmacology (A, B, or C). The GABAA and GABAC 
receptors are ligand-gated ion channels, whereas the GABAB receptor is a G-coupled protein 
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receptor. The target for the following studies is the GABAAR. In particular, the GABAAR has been 
extensively studied due to the variety of modulators that act on this receptor, including 
benzodiazepines, ethanol, general anesthetics, and barbiturates.10  
 
Figure 3. GABAA receptor.11  
The majority of the compounds investigated herein are novel GABAAR subtype-selective 
imidazobenzodiazepine scaffold as displayed in Figure 4. Both, non-selective benzodiazepines 
and selective imidazobenzodiazepine are allosteric modulators, which bind at a topographically 
distinct site from the endogenous ligand GABA and potentiate or inhibit the activity of that 
ligand (e.g. binding or signaling).12   
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Figure 4. Structures of benzodiazepines.  
During the development of selective GABAAR modulators, these compounds have been 
crucial to identify the pharmacology of different GABAAR subtypes. The subtype selectivity of 
ligands was achieved by changing their substitution patterns. Most of the 
imidazobenzodiazepines obey Lipinski’s Rules of Five and have good ADME properties. In 
addition, they contain many heteroatoms that make them well suited for analysis by mass 
spectrometry.    
1.3 Instrumental Techniques 
A mass spectrometer is an analytical instrument used to identify and quantify analytes 
based on their mass-to-charge ratio (m/z). In combination with our assays, these instruments 
enable accurate, rapid, and reproducible ADME results. The analytical methods presented 
herein are designed for inexpensive, high-throughput analyses to gain a lot of ADME 
information in a short period of time.  Mass spectrometry is both sensitive and selective, 
making it an ideal method by which to analyze compounds in complex biological matrixes. 
Tandem mass spectrometry (MS/MS) refers to ion selection, fragmentation, and detection, and 
employs multiple mass analyzers within one instrument. MS/MS allows for the absolute 
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quantification of analytes in these complex sample types. In addition, high resolution mass 
spectrometry can determine the exact mass of compounds that enable exact molecular formula 
determination. This is especially important for metabolite identification. Although this work 
does not focus heavily on metabolomics, strategies for doing such shall be discussed. Lastly, 
imaging mass spectrometry enables the visualization of the analyte spatially within whole tissue 
slices retrieved from animals dosed in vivo. This cutting-edge technology is gaining prominence 
in modern drug discovery and clinical settings. The instrument-based assays outlined herein 
determine the drug-like properties of analytes from the sub-cellular and cellular in vitro level to 
tissues and overall characteristics in vivo.  
1.3.1 High Performance Liquid Chromatography  
The first analytical technique employed in our analyses is high-performance liquid 
chromatography (HPLC). HPLC is a versatile and widely used separation technique employed in 
drug analysis to ascertain purity, quantify amounts of compound in biological samples, separate 
components of complex biological matrixes and a myriad of other applications. The sample, as a 
mixture of solutes, is contained in a liquid solvent and separated on a stationary phase via one 
of several possible retention mechanisms, including partitioning, adsorption, ion-exchange, 
size-exclusion, affinity, or chiral chromatography.13 The separations achieved with HPLC for this 
work were generally achieved by either partitioning mechanisms or adsorption. HPLC is often 
coupled to mass spectrometry to form a combination technique known as LC-MS, separating 
the analytes first by chromatography and then using the mass spectrometer as detection 
system. LC-MS is a core technique used in chemical analysis within the drug discovery arena, as 
well as many other fields. For drug discovery, many drug compounds are hydrophobic and 
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therefore well retained and may be separated by common stationary phases with HPLC. 
Similarly, many drug compounds have functional groups, such as amines, that can aid in the 
detection by mass spectrometry. Drug molecules in large part are inherently amenable to LC-
MS analysis based on the physical properties of their chemical structure.  
The history of chromatography dates back to Mikhail Tswett, a Russian botanist. Tswett 
fathered the idea of adsorption chromatography by postulating that chlorophyll was retained 
by some molecular forces on the leaf (yielding the green color) and that is why he struggled to 
extract the compound with petroleum ether. He developed a technique to separate plant 
pigments, such as chlorophylls and xanthophylls, by using a calcium carbonate stationary phase 
and a diethyl ether mobile phase.  He published this work in 1906 in Berichte der Deutschen 
Botanischen Gesellschaft, 24, 384.14  Tswett separated these plant pigment species as colored 
bands and coined the term ‘chromatogram’ as a junction of the Greek ‘chroma’, meaning color, 
and ‘graphein’, meaning writing.13   
Decades later, in 1952, Martin and Synge further defined the separation mechanisms at 
work in chromatography (and, invented gas chromatography) with the idea of theoretical 
plates.15  In this theory, which in part won them the Nobel Prize, the chromatographic column is 
envisioned as a series of many layers. These hypothetical layers exist orthogonally to the 
direction in which the analyte is moving, thereby playing a role in separation of the analytes as 
they “migrate through” the layers.  According to this theory, with every theoretical plate, 
equilibration of the solute between the stationary and mobile phase occurs (however, in reality, 
a true ‘equilibrium’ is never reached between the stationary phase and the mobile phase).  The 
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thickness of each of these layers is called the height equivalent to the theoretical plate (HETP, 
H).  The number of theoretical plates (N) is equivalent to the ratio of the column length (L) to 
the plate height (N = L/H), and varies with any given column.  This theory within 
chromatography describes the separation of analytes as being improved by increasing the 
number of theoretical plates.16 The height of the theoretical plate can be described by Equation 
1, the van Deemter equation.  
   𝐻 = 𝐴 + 
𝐵
ū
+  𝐶 ū  Equation 1.  
The van Deemter equation is a well-known model to chromatographers as a way to 
estimate the number of theoretical plates and to understand sources of band broadening.17 
Each variable in this equation impacts the chromatography, and can be used to illustrate 
challenges in chromatographic separations. The ‘A’ variable refers to eddy diffusion, which 
describes movement through a non-ideal packing material for the solid phase. Particularly in 
the early days of chromatography, stationary phases were quite roughly prepared and the 
particles packed within the column were far from uniform. The ‘B’ term refers to longitudinal 
diffusion, or how particles elute in the lengthwise direction of the column. The ‘C’ term 
describes the resistance of the analyte to mass transfer between the mobile phase and the 
stationary phase. The interaction between the analyte with respect to both phases is a key 
aspect of chromatographic separations, however that does not mean that these interactions 
are without flaws. The ‘u’ term refers to the linear velocity.16a The average of these plots shown 
as plate height vs. flow velocity can be seen in Figure 5. 
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Figure 5. Visual representation of the components of the Van Deemter equation, a plot which aids in 
describing theoretical plate height. 
The basic components of an HPLC system are shown in Figure 6. The main components 
include a solvent reservoir (typically 1L glass bottles), binary pump system, an injector (which 
can be automated or manual), an analytical column, and the detector. The detector for many 
HPLC systems is a molecular absorption spectrometer, such as a photodiode array (PDA). Many 
compounds are detectable in the ultraviolet range. Although the analytes that can be detected 
by UV are vast, the limits of detection are typically much lower for MS, therefore this work did 
not utilize UV detection systems. Other minor components include an inlet and in-line solvent 
filters, sample filters, pre-column filters (or “guard columns”), and a back-pressure regulator.18 
In recent years, ultra-high pressure HPLC (or UHPLC) has become much more common, allowing 
for much higher pressures and less of a need to regulate the pressure to a lower value. This is 
advantageous for greater peak resolution, shorter analysis times, and the ability to separate 
complex mixtures.  The LC-MS analyses presented herein were all performed using UHPLC, 
which is desirable for drug discovery applications because of the short analysis time. 
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Figure 6.  Basic schematic of HPLC.  
 
As illustrated in the Figure 6 above, the HPLC system begins with solvents from a 
reservoir, which are filtered with an inlet solvent filter to remove particulates. The solvents are 
pumped to the analytical column, and on the way the flow passes an injection valve.18 The 
injection valve is equipped with a sample loop (50 µL) and either a manual valve or, more 
commonly, an autosampler, which is preferred for high-throughput analyses. The sample loop 
allows for the repeatable introduction of sample into the flow path. The sample is then 
separated on the analytical column based on the attraction of the sample components between 
the solvent (i.e., the mobile phase) and the packing material (i.e., the stationary phase) within 
the column.18  
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1.3.2 Mass Spectrometry 
Mass spectrometry (MS) is a technique used to study molecules or fragments of 
molecules, which are separated and analyzed based on their mass-to-charge (m/z) ratio. 
Current techniques in MS involve the creation of ions in the gas phase, generally from more 
condensed phases (although not always, as is the case for gas chromatography mass 
spectrometry, GC-MS). A general scheme of the components of a mass spectrometer is 
presented in Figure 7. First developed by Francis W. Aston in 1919, it was originally employed to 
separate isotopes of neon onto a photographic plate and contributed to his award of the Nobel 
Prize in 1922.19   
 
Figure 7. Block diagram of features of a typical mass spectrometer.20 
MS is often used as a detector following chromatography and can garner both 
qualitative and quantitative information with a high level of sensitivity and selectivity. As 
described in the HPLC section above, the sample is injected and pumps are used to migrate the 
sample though separation on the analytical column. When MS is used in conjunction with HPLC, 
the pumps then pump the eluate from the analytical column to the ionization source. Ions are 
generated in the gas phase and are then separated by m/z ratio via the mass analyzer. There 
are several ionization methods for LC-MS, the most common of these being electrospray 
ionization (ESI) and atmospheric pressure chemical ionization (APCI). Mass analyzers used to 
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separate ions by mass include the very commonly used quadrupole, ion trap, and time-of-flight 
mass analyzer. Finally, a detector is employed such as an electron multiplier tube, and the 
information generated is processed and stored on a computer. A general schematic of LC-MS 
instrumentation is shown in Figure 8. 
 
 
Figure 8. Schematic diagram of a mass spectrometer with HPLC as the sample introduction system.21 
 
There are many other ionization methods available to generate gas phase ions for mass 
spectrometry, such as electron impact (EI) and chemical ionization (CI), which are the oldest 
methods and employ a gas phase sample introduction. This work has utilized exclusively 
ionization methods compatible with more condensed phases, namely evaporative ionization 
methods (ESI, APCI), and also desorption from solid phase samples by matrix-assisted laser 
desorption ionization (MALDI). Schematic representations of these methods are illustrated in 
Figure 10, Figure 11, and Figure 12, respectively.  
3.2.1 Ionization Methods 
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ESI as an ionization method for mass spectrometry was first published by John B. Fenn 
in 1988.22 A high voltage is applied to the capillary wire, while the eluent is pumped through the 
capillary, creating a very fine mist. Droplets become highly charged, and the positive charge of 
the droplets is repelled from the positive charge of the capillary.19 As the electrostatic repulsion 
exceeds the surface tension, a coulombic explosion occurs releasing ions into the gas phase. 
Meanwhile, the charge density at the surface of the droplets increases as the solvent is heated 
and evaporated (this occurs at the critical point, known as the Rayleigh stability limit). The 
instrument is operated under high vacuum and so ions and neutral molecules in the gas phase 
are drawn through the entrance cone and toward the mass analyzer.21 ESI can yield sample ions 
with multiple charges, which can be advantageous when working with larger molecules, in 
order to yield a mass-to-charge ratio (m/z) within the detection range of the mass analyzer.   
 
Figure 9. Schematic representation of ESI.13 
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Figure 10. Positive ion generation mechanism by ESI.21 
 APCI also contains a heated vaporizer, which facilitates the rapid desolvation and 
vaporization off the droplets that are sprayed from the capillary.  Reagent ions are generated 
from this solvent vapor by a corona needle discharge, which is created with a constant current 
between 2 and 10 µA leading to the formation of ions.  The energized electrons produced by 
the corona discharge ionize the flowing nitrogen gas by primary ion formation.  Ionized nitrogen 
reacts with solvent molecules, forming solvent ions through secondary ion formation.  Solvent 
ions react via a proton transfer with the sample molecules to form sample ions [M+H]+. 
Chemical ionization is an efficient method due to the numerous ion-molecule collisions. As with 
other ionization methods, charged ions and neutral molecules in the gas phase are drawn 
through the entrance cone by vacuum and travel to the mass analyzer.21 APCI yields singly-
charged sample ions and is therefore limited to molecules with masses up to about 2000 atomic 
mass units (amu).  However, APCI can allow for the ionization of less polar compounds, and can 
sometimes be a more efficient method of ionization than ESI depending on the analyte. In 
addition, on some instruments (including the Shimadzu LC-MS instruments employed in this 
work), APCI can be used in conjunction with ESI (known as DUIS mode). 
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Figure 11. Positive ion generation mechanism by atmospheric pressure chemical ionization.21 
Although ESI and APCI are the most common soft ionization techniques seen in LC-MS, 
these ionization methods are only appropriate for samples in the liquid state. Samples in the 
solid state require another ionization technique, and one such example is matrix-assisted laser 
desorption ionization, or MALDI. To create ions by MALDI, analytes are dried on a solid 
conductive surface, usually a metal plate, and coated with a matrix, which will then co-
crystallize with the analyte. A laser is fired at the sample surface and the matrix absorbs the 
energy that enables both analyte and matrix to desorbed from the surface creating an ion 
plume. The exact mechanism of the formation of this ion plume is not completely understood, 
but it is thought that the matrix absorbs energy from the laser and transfers that energy to the 
analyte. It is also believed that the analyte is desorbed as a neutral molecule and ionized by 
proton transfer from protonated matrix ions. MALDI is the method of choice for larger 
molecules such as proteins and peptides, and is employed to ionize dry solid samples into the 
gas phase. 
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Figure 12. Cartoon representation of MALDI.13 
 
3.2.2. Mass Analyzers 
In addition to the variety of ionization methods employed in this work, there are also 
several different types of mass analyzers employed based on the type of analysis performed. 
The mass analyzers used predominantly in this work are the quadrupole and time-of-flight mass 
analyzers. The most common type of mass analyzer seen is the quadrupole mass analyzer. This 
mass analyzer is an inexpensive mass filter consisting of four cylindrical rods. A constant DC 
voltage is applied to the rods modified by a radio frequency. The four rods create a “tunnel” 
where the ions are introduced, and only ions with a certain m/z possess the stable trajectory 
necessary to pass through the quadrupole to the detector (as shown in Figure 13).13    
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Figure 13. A quadrupole mass analyzer. 
It is possible to utilize more than one mass analyzer for analysis, a technique known as 
tandem mass spectrometry (MS/MS). One prevalent example is the triple quadrupole, wherein 
two quadrupole mass analyzers sandwich a collision cell, which may or may not be a 
quadrupole. So the name ‘triple quad’ can actually be a misnomer. The MS/MS instrument can 
be used to select for a specific ion (the “parent ion”), fragment this ion, and then select or scan 
for the various fragments (the “daughter ions”). Tuning the voltages of the collision cell allows 
the triple quadrupole to reproducibly create fragments for a specific analyte. Not only is the 
mass of the fragments identical each time but they are also produced in the same ratio each 
time the parent ion enters the collision cell. Therefore, the triple quad generates what are 
called “reference ion ratios”, meaning that the daughter ions seen are in a specific ratio to each 
other and to the parent ion. This relationship allows analytes to be detected at high sensitivity 
(low picomolar range), as they are identified not only by the LC retention time but also by the 
reference ion ratio spectra. Tandem mass spectrometry provides a high level of specificity to 
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the samples, which is advantageous when working with low concentrations of analytes in 
complex mixtures. 
 
Figure 14. Schematic of a triple quadrupole mass analyzer.  
The time-of-flight (TOF) mass analyzer works in a different manner than the quadrupole. 
In TOF, ions are accelerated through a potential, so they are starting with the same kinetic 
energy. Ions are then sent down a drift tube, after which they arrive at the detector at different 
times. If all ions have the same energy to start, then ions of different mass will have different 
velocities by v=(2zeV/m)1/2 and therefore arrive at the detector at different times. The flight 
tube has a known length, therefore the arrival time can be used by the instrument to calculate 
the mass: t=(L2m/wzeV)1/2. TOF based mass spectrometers are often used with pulsed 
ionization techniques (as is the case with the laser employed in MALDI-TOF) because the start 
time and position must be known.13  
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The instrument used for MS imaging studies presented herein is a TOF/TOF instrument, 
again employing tandem mass spectrometry to increase the specificity by which the instrument 
can detect analytes within complex biological matricies. The instrument has two detection 
modes, linear mode and reflectron mode. This instrument has two detectors available 
regardless of the mode chosen. In linear mode, analytes are sent through the flight tube to the 
detector without any fragmentation. This mode is typically used for very large biomolecules, 
which have larger masses that are able to be resolved by one pass through the flight tube. In 
reflectron mode, the ions are reflected to travel a longer path, which changes the ion arrival 
time and therefore enhances the resolution. This is important for smaller analytes because it is 
more challenging for the instrument to distinguish between small masses with very similar 
arrival times.13 
 
Figure 15. General schematic of a TOF mass analyzer. 23 
The MALDI-TOF instrument employed for imaging experiments has a 2 kHz solid state 
UV laser for acquisition at a wavelength of 355 nm. The diameter of the laser beam is 
adjustable from 10 to 200 micrometers. Axial spatial distribution focusing (ASDF) is a 
technology designed to address issues with the curved field reflectron, where mass resolution 
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can decrease as the instrument changes from MS to MS/MS mode.24 This mass resolution drop 
is produced by the increased spatial distribution of the ions as they leave the sample surface. 
ASDF aims to refocus this spatial distribution to keep the mass resolution independent of the 
laser power. The mass resolution should also be independent of sample thickness and 
topography. In the curved field reflectron, ions leave the MALDI source and are introduced into 
the TOF analyzer with 20 kV of kinetic energy. The ions maintain this energy as they enter the 
collision cell. The instrument employs high energy collision induced dissociation (CID), to 
generate fragments for TOF/TOF analyses. The ASDF technology is just before the reflectron 
and acts as a focusing lens for the fragment ions. The Shimadzu 7090 is designed to allow for 
mass resolution up to 10,000. Ions which are chosen to be fragmented are allowed through an 
ion gate combined with a collision gas which bombards the analytes and generates fragments. 
The fragments are then detected by passing through the flight tube completing the TOF/TOF 
analysis. 
Tandem mass spectrometry is important to achieve high specificity. Thus, tandem mass 
spectrometry provides low limits of detection (for example, 1 pg/mL sensitivity on the triple 
quadrupole instrument). This low detection limit is possible due to reference ions that are 
created and optimized for each analyte. Because LC-MS/MS analysis is specific to the fragments 
generated, analytes do not need to be baseline resolved chromatographically. When working 
with complex biological samples that are difficult to purify, the ability to select masses for 
fragmentation and use those fragments to identify analytes is important.  
3.2.3. The Detection System 
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After ions have been separated by the mass analyzer, they are detected, typically by an 
electron multiplier as illustrated in Figure 16.  The electron multiplier tube contains a conversion 
dynode, with a concave piece of metal angle that can angle the ion beam.  The off-axis 
orientation greatly reduces the noise by limiting the probability that a neutral molecule will 
strike the conversion dynode.  A high voltage is used to increase the conversion efficiency and 
thus increase the signal (Figure 17).  There is also typically a shield to protect the vacuum 
manifold from the electric field produced by the conversion dynode.21 
 
 
Figure 16. Ion detection system.21 
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Figure 17. Amplification created when the ion beam is focused onto the conversion dynode, which emits 
electrons in direct proportion to the number of ions bombarding the dynode. These electrons are 
accelerated and focused onto another dynode, thereby creating a cascading effect from dynode to 
dynode.25  
 
1.4 Conclusions 
In summary, the Arnold research group is interested in compounds that bind to the GABAA 
receptor. This work illustrates the method development for several assays to characterize drug-
like properties of lead molecules. Several different mass spectrometers were implemented to 
make these assays possible. The analytical accuracy of mass spectrometry is important and is 
therefore utilized frequently in the drug discovery arena. The work presented in the subsequent 
chapters shows how such a powerful technology can be employed to create information.   
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CHAPTER 2. Liver Microsome Stability Assay 
2.1 Introduction 
In-vitro assays used for the evaluation of ADMET (absorption, distribution, metabolism, 
excretion, and toxicity) properties are an essential part of drug discovery programs. In-vitro 
studies are generally performed to individually study these compound properties. Assays of this 
nature are extensively performed early-on to assess drug-like properties of lead molecules, 
ideally in a high-throughput and inexpensive fashion. It is important to quickly gain information 
regarding these drug-like properties when investigating a lead compound. These types of 
studies inform medicinal chemists if a drug candidate might have desirable therapeutic effects 
in vivo. With regard to metabolism within the ADMET field, optimum drug performance is 
determined largely by xenobiotic liver metabolism, because drugs taken orally are absorbed 
from the gastrointestinal tract and must pass through the liver in order to reach the circulatory 
system. Once in the circulatory system, the drug can be transported to its target organ to elicit 
a therapeutic response. However, it is rare for 100% of a dosed drug to reach the disease target 
location. A fraction of the drug is lost by xenobiotic metabolism and excretion, which is referred 
to as first-pass metabolism. A flow chart of how a xenobiotic is processed is illustrated in Figure 
18. In vitro metabolic assays can be predictive tools for first-pass metabolism, as these 
predictions are based on the metabolism of a compound in a known enzyme system. For 
example, enzymes known to exist in the liver and in other locations in the body are cytochrome 
P450 enzymes. Approximately 60% of all marketed drugs are cleared from the body by hepatic 
cytochrome P450 metabolism.26 Although both phase I and phase II metabolic processes are 
important for the metabolic processing of both exogenous and endogenous compounds, 
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typically the interactions seen in phase I metabolism are initially considered for in vitro 
metabolic studies. However, the study of metabolites generated by glucuronosyltransferase 
enzymes are commonly seen as well, and these UGT enzymes are also present in liver 
microsomes.27  
 
Figure 18. The two phases of drug metabolism and how they generate resulting metabolites.1  
The imidazobenzodiazepines investigated in this work are expected to undergo hepatic 
metabolism and generate metabolites similar to those frequently seen for benzodiazepine drug 
compounds, including hydroxylation products and benzophenone products. Figure 19 shows 
the core benzodiazepine ring featuring a pendant phenyl ring, which is a functionality seen in 
several of the lead compounds in this work. There are several prominent metabolic 
transformations that are known to occur in the liver, such as oxygenation, reduction, and 
hydrolysis, which are all dependent on the structure of the initial compound. 
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Figure 19. Illustration of benzodiazepine metabolism.28 
In order to test the metabolic stability of drug compounds in vitro, an inexpensive assay 
which can be conducted in a high throughput manner is required to efficiently screen as many 
analogs as possible. Therefore, a “mix-and-go” assay featuring commercially available reagents 
was optimized to meet this research need. Liver microsomes were chosen to provide the 
enzyme system necessary to degrade drug candidates and generate metabolites in vitro. Liver 
microsomes are subcellular fractions of liver cells, which are commercially available and have a 
reasonable cost and shelf life. Microsomes have been shown to contain drug metabolizing 
enzymes of interest such as the aforementioned cytochrome P450 enzymes (e.g. the 
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monooxygenase CYP3A4) which play a significant role in metabolizing drug compounds in the 
liver. Figure 20 shows the simple process of isolating microsomes from fresh liver tissue. 
Typically, this tissue is purchased from organ procurement sources when deemed unsuitable 
for human transplantation. The microsomes are the final product of the isolation scheme 
shown below, however assays can also be conducted using the cytosol, as well as the S9 
fraction (which is the cytosol and microsomes together).  
 
Figure 20. Isolation of microsomes from liver tissue, typically acquired through organ procurement 
organizations. Image: BD Biosciences 
Due to the fact that these enzymes are known to play such a large role in the Phase I 
metabolism in the liver, within the context of pre-clinical drug development this is one of the 
first studies performed and published when investigating new drug compounds.  Compounds 
that do not display good metabolic stability may potentially be discounted from the list of lead 
options, which is typically a lengthy list of compounds created by medicinal chemists. Generally, 
unless a compound is a pro-drug, quickly cleared compounds are considered to be unfavorable. 
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In-vitro metabolic assays can also be used to investigate reactive metabolites, drug-drug 
interactions, phenotyping, and de novo metabolite identification. Predictions can be made 
regarding how drugs will be metabolized in the liver based on known enzymatic 
transformations and previously published compounds with similar functionalities. Ultimately, 
these predictions need to be verified and this type of in-vitro assay can be used to accomplish 
that goal early-on in the drug development process. With regard to processing a xenobiotic, the 
body’s metabolism is usually attempting to clear any xenobiotics. Often metabolic enzymes will 
make compounds more polar to aid in excretion. Therefore, liver microsome assays performed 
in vitro can also be used to enzymatically synthesize and identify metabolites that would be 
excreted as well. It is very difficult to replicate an excretion system in vitro, therefore the liver 
microsome assay is currently the best option for seeking to gain excretion info ex vivo. 
Cytochrome P450 enzymes are heme-protein molecules. The heme group 
(protoporphyrin IX) contains coordinated iron. It has been proposed that the substrate binds to 
the active site followed by a reduction of the iron III of cytochrome P450 to the iron II state, by 
a one electron transfer catalyzed by P450 reductase. Subsequently, molecular oxygen binds to 
the iron II and is converted to an activated oxygen species.29 This system can be non-specific 
and will oxidize a variety of substrates. Non-selective enzymes such as CYP3A4 metabolize a 
large number of drugs including our current analytes of interest, imidazobenzodiazepines. 
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Figure 21. Crystal structure of the midazolam-bound CYP3A4.30 
In addition to identifying potential metabolites utilizing CYP450 enzymes, several numeric 
parameters can be estimated from the in-vitro degradation of compounds by liver microsomes. 
The assay presented herein estimates the rate of metabolism based on the free intrinsic 
clearance, which is a description of metabolism due to enzyme activity alone (other factors 
such as blood flow through the liver or drug binding percentages are not accounted for in the 
calculation of intrinsic clearance).31 The values calculated for the clearance are based on the 
Michaelis-Menten kinetic model in biochemistry, which is outlined in Equation 2. Under linear 
conditions, as is the case with the liver microsome assay, the concentration at the enzyme site 
is 10% or less of the Km, and equation 2 is reduced to form Equation 3.  
Equation 2.  Rate of metabolism = Vmax*CE / Km + CE 
Equation 3.  Rate of metabolism = Vmax*CE / Km 
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The rate of metabolism is equal to the product of the intrinsic clearance and the 
concentration of drug, and is expressed as μL/min/mg microsomal protein. The analogy 
extended to an in vivo situation would be the volume of blood that is cleared of a drug per unit 
time. Based on the same kinetic model, the metabolic half-life of the drug can also be 
calculated (the time taken for the concentration of a drug to be eliminated to half of its original 
value). This procedure has been optimized using both human and mouse liver microsomes to 
identify any metabolic differences between species, as most pre-clinical assays are conducted in 
mice. Drugs can behave differently in certain animal species, therefore it is necessary to 
conduct this assay with both human and mouse liver microsomes to illustrate the metabolic 
behavior in animal and human.   
2.2 Materials & Methods 
 
Four µL of 1 mM test compound (XHE-III-74 ethyl ester or XHE-III-74-Acid at a final 
concentration of 10 µM) in DMSO were preincubated at 37°C for 5 minutes on a digital heating 
shaking dry bath (Fischer scientific, Pittsburgh, PA) in a mixture containing 282 µL of water, 80 
µL of phosphate buffer (0.5 M, pH 7.4) 20 µL of NADPH Regenerating System Solution A (BD 
Bioscience, San Jose, CA) and 4 µL of NADPH Regenerating System Solution B (BD Bioscience, 
San Jose, CA) in a total volume of 391.2 µL. Following preincubation, the reaction was initiated 
by addition of 8.8 µL of either human liver microsomes (BD Gentest, San Jose, CA), or mouse 
liver microsomes (Life technologies, Rockford, IL at a protein concentration of 0.5 mg/mL. 
Aliquots of 50 µL were taken at time intervals of 0 (without microsomes), 10, 20, 30, 40, 50 and 
60 minutes. Each aliquot was added to 100 µL of cold acetonitrile solution containing 1 µM of 
verapamil HCL as internal standard. This was followed by sonication for 10 seconds and 
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centrifugation at 10,000 rpm for 5 minutes. 100 µL of the supernatant was transferred into 
Spin-X HPLC filter tubes (Corning Incorporated, NY) and centrifuged at 13,000 rpm for 5 
minutes. The filtrate was diluted 100 fold and subsequently analyzed by LC-MS/MS with 
Shimadzu LCMS 8040, (Shimadzu Scientific Instruments, Columbia, MD). The ratio of the peak 
areas of the internal standard and test compound was calculated for every time point and the 
natural log of the ratio were plotted against time to determine the linear slope (k). The 
metabolic rate (k*C0/C), half-life (0.693/k), volume of distribution (Vd = volume of the assay (µL) 
divided by the protein of the incubation in mg (2000 µL/mg in our assay)), and intrinsic 
clearance (Vd*ln2/t1/2) were calculated, where C0 is the initial concentration of test compound, 
C is the concentration of microsomal protein. All time points were repeated in triplicate. Human 
and mouse liver microsomes were purchased as a 50 donor pool to ensure sufficient diversity 
for reproducible assay results. NADPH is a necessary co-factors for enzymatic activity, therefore 
when this fuel for the enzymes has been used up in its entirety, the enzymes can no longer 
metabolize xenobiotics and the conversion will stop. HyClone phosphate buffered saline was 
purchased from Fisher Scientific (Waltham, MA). The initial development of this assay was 
performed on a Thermo HPLC with a PDA detector. Further optimization and metabolite 
identification was performed on a Shimadzu 8040 triple quadrupole UHPLC-MS/MS system as it 
became available. Optima LC/MS grade methanol, acetonitrile, formic acid and water were 
purchased from Fisher Scientific.  Separation was performed on a Restek C18 column (25 mm x 
2.1 mm, 3 µm particle size). Uracil was purchased at Sigma Aldrich (Milwaukee, WI) and used to 
measure the instrument void time. Test compounds were synthesized as published previously32 
and received as pure powder, which was weighed and dissolved in DMSO to create original 
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stock solutions at [10mM]. Stock solutions were diluted to a working concentration of 1 mM, 
also in DMSO, as described above. Microsomes were stored at -80°C prior to use and thawed 
over wet ice. All solutions purchased (NADPH and microsomes) were aliquot into smaller 
volumes to minimize the number of freeze/thaw cycles. Solutions A contains NADP+ and 
solution B contain glucose-6-phosphate dehydrogenase to create NADPH when combined. The 
initial assay solutions consisted of a mixture of 200 µL total, 10 µL of solution A, 2 µL of solution 
B, 2 µL of 1 mM stock in DMSO were added to 181 µL of PBS. However this volume was 
increased over time to allow for additional replicates. This mixture was pre-incubated for 5 
minutes to reach physiological temperature, followed by the addition of 5 µL microsomes (20 
mg/ml protein concentration). Initially, 30 µL of the microsomal assay mixture was taken out at 
time points 0, 5, 10, 15, 30 and 60 minutes and immediately added to 1 equivalent volume of 
cold acetonitrile containing a pre-chosen internal standard. However, these time points were 
altered to be every ten minutes, to generate more consistent plots. The acetonitrile used to 
precipitate the protein was upgraded from standard reagent grade to LC-MS grade when the 
methods were to be run on the LC-MS/MS instrument. In the original development of this 
assay, the quenched mixture was spun down at 10,000 rpm for 5 minutes, the supernatant 
withdrawn from atop the protein pellet, transferred to a 384 well plate and placed directly onto 
the HPLC-UV instrument. However, additional filtration steps were later added prior to LC-MS 
analysis, using 0.22 μm nylon spin filter vials. Although all particulates and large proteins should 
be removed from the acetonitrile by precipitation and centrifugation, it was determined that 
additional filtration was necessary to generate clean, consistent data on the LC-MS 8040. This 
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procedure was developed in duplicate and increased to triplicate repeats for more reliable 
results and lower standard deviation values.   
Initial method development and analyses were performed on a Thermo LTQ HPLC-UV 
instrument. However, shortly after this assay was developed the method was transferred to the 
triple quadrupole UHPLC-MS/MS instrument (Shimadzu 8040). The initial analysis conditions 
performed on the now decommissioned HPLC-UV system were under isocratic conditions, 30% 
acetonitrile and 70% water. The flow rate was 150 μL/min, with a column oven temperature of 
50°C and a pressure of 75 bar. This instrumental method was problematic due to a consistent 
yet sloping baseline, as pictured in the chromatogram below.  Although the peak shape is 
sufficiently symmetrical and the signal to noise ratio is calculated as infinite, it is not ideal to 
have such a baseline. HPLC-UV also shows a large solvent front, which is not seen on the LC-
MS/MS instrument, as MS/MS methods are specific to the masses of interest. Although the 
HPLC-UV chromatogram shows sufficient baseline separation for each peak, as well as sufficient 
signal to noise, the peak shape does illustrate some tailing, and the proximity of the first peak 
to the solvent front is somewhat concerning. Typically this issue can be remedied with 
modifications to the mobile phase conditions, such as switching from acetonitrile to methanol, 
decreasing the flow rate, or increasing the water content in the mobile phase. However, these 
typical troubleshooting strategies were not sufficient for the analysis initially because the C18 
column was well past retirement. Column care is exceptionally important for the lifetime of the 
column in liquid chromatography, if the column is stored uncapped or not handled carefully, it 
will dry out the stationary phase and deteriorate the column’s ability to sufficiently retain 
analytes.   
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Figure 22. HPLC-UV analysis of drug compound degradation by human liver microsomes. The peaks 
shown are the solvent front (tr: 0.52 min), the analyte (tr: 0.99 min), and the internal standard (tr: 2.59 
min). RT is retention time, AA is the area of the peak, AH is the peak height, and SN is the signal to noise 
ratio. 
Upon implementation of the triple quadrupole instrument, a new C18 column was 
purchased for microsomal assay analysis. Analytes were optimized individually by testing 
collision energies from -15 to -40 V in positive mode, tested in increments of 5. Proposed 
fragmentation patterns for analytes are listed in Appendix A. Masses and voltages used for 
Analyte k = 0.9038 
Internal Standard k = 3.9808 
α = 4.42 
Rs = 4.71 
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reference ion ratios are listed in Appendix B. All fragmentation patterns were optimized with 
pure compounds dissolved from powder into mobile phase.  
 
Figure 23. Chromatogram from the triple quadrupole LC-MS 8040. Each peak represents the total ion 
chromatogram followed by each ion in the reference ion ratio (underlying peaks). For example, the peak 
at RT 4.4 minutes is for verapamil. The largest peak in blue is a sum of all the ions for that compound. 
The second largest peak in light blue is for most abundant of the reference ions, followed by smaller 
peaks in red and black for the less abundant reference ions for verapamil.  
2.3 Results and Discussion 
Peak areas were integrated by LabSolutions software and the analyte area was divided 
by the area of the internal standard, to create a ratio. This ratio was converted to a percentage 
by taking the zero time point as 100% and scaling the ratio values to that assumed zero. Then, 
to compute pharmacokinetic parameters, the natural log of the percentage was plotted and fit 
with a linear regression (as illustrated in Figure 24). The metabolic half-life was calculated by 
taking the natural log of 2 divided by the slope of the regression line. The volume of distribution 
for our assay was 2000 μL/mg. That volume of distribution was the multiplied by the ln(2) and 
divided by the previously calculated metabolic half-life to yield the internal clearance. The 
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metabolic rate is determined by the slope of the regression line multiplied by the concentration 
of compound (10000 nM) and divided by the concentration of protein (500 mg/l).  
 
Figure 24. Example of calculations performed for liver microsome assays.  
 
Figure 25. Percentage plot of human liver microsome results for α5β3γ2 and α4β3γ2 GABAAR selective 
ligands.  
 
Slope of regression line = 0.005904 
Half-life: ln(2)/slope 
0.693/0.0059 = 117.5 minutes 
Clearance: Vd*ln(2)/half-life 
2000μL*0.693/117.5 = 11.8 
μL/min/mg protein 
 
Metabolic Rate: Slope * 
[compound]/[protein] 
0.0059*(10 000 nM/l)/(500 mg/L) = 
0.118 nmol/min/mg 
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Table 1. Metabolic parameters for seven imidazobenzodiazepine compounds. 
Compound HZ-166 MP-II-069 MP-II-068 Xhe-III-74 
Xhe-III-74 
EE 
MRS-I-36 CMD-45 
Metabolic 
Half Life, 
minutes 
117.46 116.20 200.58 663.79 334.94 2252.93 4129.92 
Intrinsic 
Clearance, 
uL/min/mg 
11.8 11.9 6.9 2.1 4.1 0.6 0.3 
Metabolic 
rate, 
nM/min/mg 0.118 0.119 0.069 0.021 0.041 0.006 0.003 
                             
                    
Figure 26. Structures correlating with the results for several imidazobenzodiazepine compounds.  
  
Figure 27. α4β3γ2 selective ligands, natural log plot. 
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Figure 28 α5β3γ2 selective ligands, natural log plot. 
 
 The results for this assay show a distinct difference in metabolic stability between the 
α4β3γ2 selective GABAAR ligands and the α5β3γ2 selective GABAAR ligands alpha 5 receptor 
ligands. The compounds that are selective for the alpha 4 receptor have an extra ring attached 
directly to the core structure, in a rigid position that will prevent metabolism at the 4 position 
of the seven membered ring. The alpha 5 receptor ligands, however, do not have a ring in this 
position, they have a pendant phenyl ring that is designed to fit into the binding pocket (as 
shown in the structures in Figure 26). These structural differences lead to subtype selectivity, 
but also have an impact on the in vitro stability of these compounds.   
This assay can also be used to identify metabolites that are generated by CYP450 
enzymes. Although the quantitation is done in MRM mode, which identifies a specific mass and 
subsequently fragments of that mass, the assay samples can also be scanned over a mass range 
in an attempt to identify metabolites. General scans can be performed on a quadrupole 
instrument, but for more detailed analysis and formula prediction, the high resolution IT-TOF 
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presents the opportunity to research in depth metabolomics. One such example of a newly 
discovered metabolite generated through the microsome assay is presented in Figure 29. The 
hydroxylation product for the MP II 069 compound was identified in scan mode on the LC-MS 
8040 at the 60 minute time point. As this time point, which is at the end of the assay, enzymatic 
transformations have occurred and therefore metabolites are present in the solution. 
 
Figure 29 Scheme of the metabolism of MP II 069 by hydroxylation.  
Metabolomics is in and of itself a vast research area within the field of drug discovery. 
With the resources available to the MIDD, this is a promising future direction that the medicinal 
chemists at UWM will be able to pursue to further understand the pharmacological promise of 
lead compounds.  
This assay has been successfully developed to investigate the metabolic stability of 
various lead compounds under in vitro conditions. This procedure has been implemented to 
study not only imidobenzodiazepines synthesized by the Cook group, but other compound 
types as well for a variety of projects. Prior to the development of this assay, medicinal 
chemists at UWM would be required to utilize external contract research organizations for 
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metabolic stability studies. One such example is the compound HZ-166, which was investigated 
by a contract research organization as published previously.33 The assay presented above shows 
good correlation with the CRO results (indicating this compound to have 66% of the parent 
remaining after one hour), further illustrating the effectiveness of the method presented.  
In conclusion, this assay is a commonly used screening tool that has been implemented 
in the MIDD to screen over 100 compounds to date. This assay provides a sufficiently high-
throughput approach to the assessment of metabolic stability.  
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CHAPTER 3. Primary Human Hepatocyte Assay 
3.1 Introduction 
 Assays which employ human liver microsomes to illustrate analyte degradation give 
medicinal chemists valuable information regarding in-vitro stability of lead compounds because 
they contain important drug-metabolizing enzymes such as CYP450 enzymes. However, 
microsomes do not contain the full complement of enzymes that a drug will encounter during 
metabolism in the liver.26 Although the liver microsome assay is rapid, inexpensive, and 
therefore useful in high-throughput screening, it can be necessary to carry out additional 
metabolic stability assays using cell culture. To gain insight into the metabolism a drug will 
encounter in the liver, it is obvious to use a liver cells for in-vitro screening. These so called 
hepatocytes can be harvested directly from liver tissue and can be cultured for a limited period 
of time. An alternative is the use of immortalized or carcinogenic liver cells that can be 
propagated unlimited in cell culture. Freshly isolated liver cells are called primary human 
hepatocytes, which have become the “gold standard” for looking at hepatic clearance as well as 
identifying drug metabolites in-vitro. It is important to mention that liver microsome contain 
less enzymes than the hepatocytes they are derived from. One example are transport proteins 
that may play a role in the performance of a drug compound.34 Typically, primary human 
hepatocytes are isolated from livers deemed unsuitable for transplantation and are relative 
expensive. They can be plated and cultured, however the maximum time that they will typically 
live is a few days. Therefore, the use of primary human hepatocytes, while it is the best case 
scenario for gaining insight into the hepatic clearance of a drug in Phase I metabolism, is far too 
expensive to employ for a high throughput preclinical assays. For that reason, it is typical 
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practice to use liver microsomes to screen a large number of compounds, and only the most 
promising lead compounds are investigated with a hepatocyte based metabolism assay.  
 In addition to the high cost and limited life span of freshly isolated primary human 
hepatocytes, they are also phenotypically unstable and exhibit large variations between donors 
when mixed.35 Commercially available human liver microsomes are typically pooled from 50 
donors in order to eliminate large variations. This is not an option for primary hepatocytes. 
Alternatively, utilizing a hepatoma cell line (derived from cancer cells) has become a more cost 
effective research option. Several cell lines currently exist as options, and are employed for this 
purpose. These include HepG2, Hep3B, Huh7, HBG, HepRG and PLC/PRFs.35 In general, cell lines 
derived from cancer cells easy proliferate. HepG2 cells have lost some functionality since their 
initial establishment as a hepatoma cell line, however, drug-metabolizing potentials can still be 
characterized for each cell line and are shown to be of use in drug discovery programs. 
Typically, suppliers of these cell lines will characterize pertinent proteins (such as cytochromes) 
expressed by these cells. With regard to xenobiotic metabolism, these cells generate some of 
the metabolites that would be formed in vivo, although the quantitative amounts are different. 
This makes sense because the human body has many different organs responsible for 
metabolism and therefore the number and quantity of enzymes available to process a drug are 
clearly very different from cell culture. The quantity of parent compound and metabolites 
varies based on the chemical composition, amount of compound, number of cells, media and 
temperature. Both Phase I and Phase II metabolizing enzymes can be transcriptionally induced 
in cell culture and will change with the culture conditions. Primary cells from different donors 
inherently have very high batch variability but represent the different metabolism by patients 
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taking these drugs eventually. However, this variability is a disadvantage when it comes to 
reproducible quantification of generated metabolites and parent drug degradation. Hepatoma 
cells don’t change their genetic makeup in culture thus metabolic stability assay results are 
more uniform. Therefore, HepG2 are a useful substitute for assay development and have been 
employed in the studies listed herein.  
3.2 Materials & Methods 
 HepG2 cells were purchased from ATCC (Manassas, VA) and were stored in liquid 
nitrogen prior to use. Cells were quickly thawed at room temperature and added to 20 mL of 
Minimum Essential Medium (Hyclone, #SH3024301) media in a culture flask to which  non-
essential amino acids (Hyclone, #SH30238.01), 5 x 106  units of penicillin and streptomycin 
(Hyclone, #SV30010) and 10% of heat inactivated fetal bovine serum (Gibco, #10082147) were 
added. The cells were grown for 3 days at 37° C with 5% CO2, trypsinized with 0.25% Trypsin 
(Hyclone, #SH3004201) for 5 minutes to detach from the cell culture flask and were then added 
to 20 mL fresh MEM media. Cells were spun down in conical tubes at 1000 rpm for 3 minutes, 
resuspended in a smaller volume of MEM media and counted with a hemocytometer at 4.2 
million cells per mL. Cells were diluted 2x with additional MEM media and aliquots of 100 μL 
were dispensed into wells of a sterile 96 well plate (Nunc #12-566-71). 0.5 μL of compound (2 
mM in DMSO) at different concentrations was dispensed into each well of the 96 well plate for 
a final incubation concentration of 10 uM (0.5% DMSO). The plate was incubated for 24 hours 
at 37° C with 5% CO2. 65 µL of media was aspirated and combined with 130 µL of cold 
acetonitrile solution containing 1 µM of verapamil HCL as internal standard. This was followed 
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by sonication for 10 seconds and centrifugation at 10,000 rpm for 5 minutes. 100 µL of the 
supernatant was transferred into Spin-X HPLC filter tubes (Corning Incorporated, NY) and 
centrifuged at 13,000 rpm for 5 minutes. The filtrate was diluted 100 fold and subsequently 
analyzed by LC-MS/MS with Shimadzu LCMS 8040, (Shimadzu Scientific Instruments, Columbia, 
MD). The ratio of the peak areas of the internal standard and test compound was calculated for 
every time point and the natural log of the ratio were plotted against time to determine the 
linear slope (k). The half-life (0.693/k) was calculated.  
3.3 Results & Discussion 
 Several compounds were screened using the HepG2 cell based assay. Initially, the first 
compound chosen was MP III 024 (Figure 30), which was incubated for 90 minutes with HepG2 
cells. Unlike for the liver microsome assay, no notable change in the concentration of MP III 24 
was observed for a period of 90 minutes. Therefore, after this initial run it was decided to 
extend the timeline of this assay to two hours (Figure 31).   
 
Figure 30 Structures for α5β3γ2 GABAAR selective ligands.  
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Figure 31. Results for α5β3γ2 GABAAR selective ligands in HepG2 cell stability assay, presented as percent 
compound remaining over the course of two hours. The left plot shows the linear regression from 65 to 
100%, the right plot shows the percent scale from zero to 100%. 
 We observed that all three compounds were relative stable in the presence of HepG2 
cells. In comparison the half-lives in the presence of liver microsomes were 167 minutes SH-
053, 209 minutes MP-III-024 and 158 minutes Hz-166. The calculated stability parameters for 
HepG2 cells are presented in Table 2.  
Table 2. Stability parameters for α5β3γ2 GABAAR selective ligands. 
Compound Half Life, min R square Sy.x 
Deviation from 
linearity 
MP-III-024 432.1366 0.9069 0.01862 Not significant 
SH 053 647.1962 0.5197 0.04819 Not significant 
HZ 166 423.9432 0.7924 0.04225 Not significant 
 
The half-lives of α5β3γ2 GABAAR selective ligands were lower than those determined with the 
liver microsome stability assay. It is generally known that microsome stability assays actually 
overestimate the internal clearance for a compound, as illustrated in Figure 32. The clearance 
of these FDA approved GABAAR ligands is significantly faster in microsomes that in the presence 
of fresh hepatocytes.  The data seen in this work is thus consistent with the trend published in 
the literature. 
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Figure 32. Comparison of CL values for five benzodiazepine compounds as estimated in human liver 
microsomes, human cryopreserved hepatocytes, and fresh human hepatocytes.36 
 The assay described herein involves a living cell system, therefore many factors 
contribute to the repeatability of this assay. HepG2 cells are an adhesion cell line thus they 
grow on the flask bottom. A substance called matrigel is often used to assist in adhering cells to 
plastic surfaces during cell culture. This assay was tested both with and without matrigel. 
However, it was determined that the addition of this material to the assay plate did not have 
any noticeable effect the results of this assay. 
 During the time this assay was being developed, the Cook group synthesized many 
deuterated analogs in an effort to exploit the kinetic isotope effect for metabolic stability. A 
carbon-deuterium bond is more difficult to break than is a carbon-hydrogen bond, thus it is 
expected that the deuterated analogs would display better stability in both the human liver 
microsome assay as well as the hepatocyte assay. The kinetic isotope effect is a commonly 
studied phenomenon in the field of drug development and was therefore a logical strategy for 
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the medicinal chemists synthesizing compounds for this work to increase metabolic stability. 
The compounds investigated were α4β3γ2 GABAAR selective ligands (Figure 33). 
 
 
Figure 33. Structures of α4β3γ2 GABAAR selective ligands . 
Also these compounds were investigated with the developed HepG2 cell stability assay and the 
results are summarized in Figure 34.  
 
Figure 34. Results for four α4β3γ2 GABAAR selective ligands in HepG2 cells. 
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We observed that the four compounds displayed different stabilities in the presence of HepG2 
cells. In comparison the percentage left after 60 minutes in the presence of liver microsomes 
was 59% XHE-III-74, 65% XHE-III-74 OCD3, 77% XHE-III-74 ethyl ester, and 99% XHE-III-74 ethyl 
ester OCD3. The calculated stability parameters are presented in Table 3.  
Table 3. Stability parameters for α4β3γ2 GABAAR selective ligands. 
Compound Half Life, min R square Sy.x 
Deviation from 
linearity 
Xhe III 74 184.2007 0.8708 0.0627 Not significant 
Xhe III 74 OCD3 255.3969 0.4782 0.1233 Not significant 
Xhe III 74 EE 293.4577 0.7313 0.0619 Not significant 
Xhe III 74 EE OCD3 2690.7887 0.0287 0.0662 Not significant 
 
 Figure 34 showed that little variation in hepatocyte stability between the OCH3 and OCD3 
analogs for the original Xhe III 74. However, for the Xhe III 74 Ethyl Ester compound, the 
substitution of the OCH3 to the OCD3 did appear to increase the metabolic stability in the cell-
based assay based upon this plot. However, upon closer evaluation at the 95% confidence 
interval, the data can be assessed for a slope that deviates significantly from zero. Due to the 
larger error bars for the Xhe III 74 OCD3 compound (shown in blue) this statistical test does 
show that for both the OCD3 analogs, the slope does not deviate significantly from zero, 
whereas the original lead compounds without deuterium do significantly deviate from zero. 
These preliminary assay results do indicate that the substitution from OCH3 to OCD3 does in fact 
increase the metabolic stability of the compound.    
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Figure 35. Xhe III 74 and its deuterated analog shown with the 95% confidence interval. 
  
Figure 36. Xhe III 74 Ethyl Ester and its deuterated analog shown with the 95% confidence interval. 
  
The linear regression results for the α4β3γ2 GABAAR selective ligands presented in Figure 35 and 
in Figure 36 as shown for the deuterated and non-deuterated version of each compound, with 
the error bars bracketed for the slope of the linear regression at the 95% confidence interval 
(shown in dashed lines).  
 The intrinsic clearance estimated by in vitro metabolic assays such as the liver 
microsome stability assay and the hepatocyte cell-based assay provide useful information 
regarding both Phase I and Phase II metabolism of drugs in the liver. We have successfully 
established a cell-based metabolic assay for the assessment of compound stability in vitro. The 
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assay can be carried out with the inexpensive HepG2 cells. In the future, this assay can be 
adapted with slight modifications to test compounds in fresh or cryopreserved human 
hepatocytes.  
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CHAPTER 4. In vitro Brain Metabolism Assay 
4.1 Introduction 
Stereochemistry is an important consideration in drug development. Stereoisomers are 
compounds with the same molecular formula and bonds, but different three dimensional 
structures. Stereoisomers are divided into subcategories of enantiomers (mirror-images) and 
diastereoisomers (non-mirror images).37 It is important to consider the spatial arrangement of 
the atoms within a drug compound because the three-dimensional orientation of the functional 
groups must fit into the three-dimensional binding pocket of the target receptor. Therefore, the 
drug-like properties of a molecule can be greatly impacted by variations in stereochemistry. 
Approximately 25% of drugs currently on the market are comprised of a mixture of 
stereoisomers, however the biological activity may be predominantly or wholly induced by one 
stereoisomer in the mixture. One simple example is ibuprofen, in which the R conformation is 
inactive but the S isomer displays the therapeutic effect.1-2 This drug is sold as a racemic 
mixture. While some components of a racemic mixture may display no effects, enantiomers can 
also display different physicochemical properties resulting in adverse effects or toxicity.37 
Proteins are composed of amino acids, which are chiral molecules, thus differing stereoisomers 
may interact differently with a particular protein. The classic example of the dangers of 
stereoisomerism lies in the story of thalidomide.2 This compound was prescribed as an anti-
nausea medication to pregnant women and the alleviation of the symptoms of nausea was a 
result of the R enantiomer of this drug. However, the S enantiomer caused birth defects. For 
this reason, this drug cannot be sold as a racemic mixture. Furthermore, even if this drug was 
synthesized and marketed as a single enantiomer, the R enantiomer alone, the body actually 
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creates a racemic mixture. Thalidomide (Immunorin or Contergan) caused limb deformities in 
many children in the 1960’s, as a result of restricted blood flow to developing limbs.38 
Serendipitously, thalidomide is investigated as a potential anti-cancer drug, for types of tumors 
that require an ample blood supply to grow.2, 39    
 
Figure 37. The S and R isomers of Thalidomide, which are effective, and dangerous, respectively. 
Herein, we describe the investigation of the S and R enantiomers of chiral 
imidazobenzodiazepines that bind the GABAA receptor in the brain. As a pentameric receptor, 
the GABAA receptor contains five subunits, typically two α, two β, and a fifth, often γ subunit.10 
This assembly has multiple variations for each of these receptor subunits. GABAA receptors 
contain α1, α2, α3 or α5 subunits together with a neighboring γ2 subunit, which is where 
benzodiazepines act as positive allosteric modulators. However, less than 5% of all GABAA 
receptors in the brain have α5 subunits however α5β3γ2 GABAARs are common in the spinal 
cord.40 Therefore, this receptor has been targeted by the Cook group and other as a therapeutic 
strategy for neuropathic pain.41 Through pharmacokinetic studies of a particular compounds of 
interest, SH-053-2’F-R/S-CH3 was identified as lead compound and differences were seen in vivo 
with regard to concentrations of its enantiomers in rat brain. To investigate the hypothesis that 
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the enantiomers have different stability in the brain, an in vitro metabolic assay was developed 
to investigate the differences between the R and S stereoisomers.   
 
Figure 38. Structures of chiral α5β3γ2 selective GABAAR ligands and a proposed metabolite of both 
isomers identified in vivo. 
We have shown in previous assays such as the liver microsome assay and the 
hepatocyte assay that the activity of cytochrome P450 enzymes plays a crucial role in Phase I 
xenobiotic metabolism. Although it is well known that these enzymes are present in large 
quantities in the liver, recently it has been demonstrated that many of these enzymes are also 
present in the brain.42 Examples of CYP450s that have been identified in both tissues are 
displayed in Figure 39. 
 
Figure 39. Known cytochrome enzymes and their identified substrates.42 
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 Therefore, the brain metabolism assay aims to gain information regarding drug-metabolizing 
enzymes in the brain and enable later comparison with the in vivo PK results.  
 
4.2 Materials & Methods 
Male Wistar rats (250-350 g.) were housed in pairs and kept on a 12h dark/light cycle 
(lights on at 7:00 am) with food and water provided ad libitum. For testing, a single rat was 
euthanized (asphyxiated via CO2 chamber) in accordance with IACUC, and decapitated with a 
small animal guillotine. The brain was extracted and weighed by difference into a 15 mL conical 
tube. One equivalent of pre-heated PBS (37°C) was added by mass and the mixture was 
homogenized with a LabGen T2 homogenizer. Individual centrifuge vials (1.5 mL) were prepared 
(100 μL PBS, 20 μL of a 100 μM stock solution of test compound, 80 μL brain homogenate) for 
eight (0, 10, 30, 60, 120, 240, 480, 1440 min) time points and placed in an oscillating heat-block 
(37°C, 300 rpm). At each time point, the reaction vial was quenched with double the volume of 
cold acetonitrile (400 μL) containing a 10 μM internal standard (HZ-166) and placed on ice. The 
vials were vortexed and centrifuged (10,000 rpm) for three minutes and the supernatant was 
pipetted into a spin filter centrifuge tube (0.22 micron nylon) for filtration. Samples were 
diluted 20x into Optima LC-MS grade methanol (Fisher Scientific) by pipetting 25 μL of 
supernatant solution into 475 μL methanol in a glass autosampler vial. Samples were analyzed 
using a Shimadzu LCMS-8040. Three independent experiments were performed (n = 4 for each 
independent experiment). 
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4.3 Results  
 The graphs shown in Figure 40were created by the Savic group following a 
pharmacokinetic study of both the R and S isomers of the SH-053-2’F-R/S-CH3 compound in 
Wistar rats.33 The concentrations found for both isomers in the brain were comparable, 
however the concentrations seen for the S isomer in plasma were an order of magnitude below 
that of the R isomer.     
 
Figure 40. Pharmacokinetic profiles of the R and S isomers of the SH-053-2’F-R/S-CH3 compound. 
 The pharmacokinetic profiles displayed above show a discrepancy between the plasma 
concentrations of SH-053-2'F-S-CH3 and SH-053-2'F-R-CH3. One hypothesis is that both SH-053-
2’F-R/S-CH3 undergo active transport into the brain thus even at a low blood concentration for 
SH-053-2'F-S-CH3 a high brain concentrations can be reached. The clearance of SH-053-2'F-S-
CH3 is fast, which has been confirmed by human liver microsome stability assays that indicated 
that the S enantiomer is degraded at a faster rate than the R enantiomer. In addition, 
comparing the concentrations of both stereoisomers in the brain, we observed a faster 
clearance of SH-053-2'F-S-CH3 than SH-053-2'F-R-CH3 in the brain.  
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Thus, to investigate if transport or brain metabolism are the underlying processes a brain 
metabolism assay is carried out.  This ex vivo assay utilizes fresh brain homogenates and 
compounds are incubated at 37°C. The compounds are quantified at different time points and 
the results are summarized in Figure 411.  
 
Figure 41. Results of the brain homogenate assay displayed as a percentage remaining as well as the 
linear regression (and the 95% confidence interval). 
SH053-2'F-R-CH3 compounds were incubated with rat brain homogenate and quantified 
by LC-MS/MS. The results are presented as a percentage remaining over the course of 24 hours 
(three independent assays with an N=4 replicates for each assay). The results of this assay are 
fitted with a linear regression to calculate metabolic half life, as with the microsomal stability 
and hepatocyte assays. Based on the linear regression the slope was used the calculated the 
half-life and other pharmacokinetic parameters summarized in Table 44.  
Table 4. Estimated metabolic parameters for the R and S isomers in brain tissue homogenates. 
 
Compound Half Life, min
Internal Clearance, 
uL/min/mg
R square Sy.x
Deviation from 
linearity
SH-053-2'F R CH3 7369.2024 0.0188 0.3426 0.0570 Not significant
SH-053-2'F S CH3 1607.8571 0.0862 0.8419 0.0931 Not significant
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The results of the brain stability assay show that the S-isomer (50% remaining after 24 hours) 
was degraded at a faster rate than the R-isomer (84%). The half-life of SH-053-2'F-R-CH3 in the 
brain is 4.5 times longer than SH-053-2'F-S-CH3.  
4.4 Discussion 
In addition to the pharmacokinetic data presented above, the Savic group identified a 
potential metabolite of mass 267.25 g/mol at a ratio of 10:1 when derived from the S isomer 
(ratio of metabolite:parent), whereas the R isomer yielded the same metabolite at a ratio of 
1:10. Although the data regarding this proposed metabolite is consistent with the idea that the 
S isomer is more readily metabolized than is the R isomer, this metabolite was not seen in the 
brain homogenates assay, and therefore cannot be quantified at this time.  
These results show a clear trend in the difference between R and S isomers when 
exposed to metabolic enzymes in the brain. The P value for the comparison of these slopes is 
P<0.0001, meaning that if the overall slopes were identical, there would be less than a 0.01% 
chance of randomly choosing data points with slopes as different as those presented above. 
Therefore we can conclude that the differences seen between the slopes in this assay are 
extremely significant. This brain metabolism assay is a relatively low-cost method with rapid 
analysis times to view the degradation of drug compounds in fresh brain homogenates. If this 
assay is to be continued in the future, one could investigate the viability of freezing brain 
homogenates at -80°C for a quicker sample preparation setup, or isolating the drug 
metabolizing enzymes within sub-cellular fractions as is done for the liver microsome stability 
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assay. These future directions have not yet been tested, leaving room for additional in vitro 
development with regard to brain metabolism of drug compounds.  
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CHAPTER 5. Quantification of GABA with a novel HILIC based method 
5.1 Introduction 
Ion channels are transmembrane proteins that contain a central pore to establish and 
control voltage potentials across cell membranes. They do this by controlling the active flow of 
ions between the intracellular and extracellular environments. This family of proteins is 
involved in a diverse array of physiological functions, therefore ion channels are popular 
therapeutic targets in drug discovery today.43 The lead compounds for the drug development 
projects outlined in this work are modulators of the GABAA receptor. This receptor is a ligand-
gated ion channel, where gamma amino butyric acid is the endogenous ligand, and binding of 
this ligand controls the flow of chloride ions through the channel. Typically, the flow of chloride 
ions through this receptor is governed by GABA. The binding of a GABAA receptor agonist (such 
as a drug compound) to the receptor will modify the flow of chloride ions. This flow of ions can 
be measured to test compound effects on the receptor, using ion channel screening assays (e.g. 
ligand binding, patch clamp, fluorescence and luminescence based assays, and 
electrophysiology). These assays are conducted in vitro thus it is paramount to understand the 
circumstances and conditions in the organism itself to recapitulate similar conditions in vitro. In 
the case of GABA, it has been well documented that T cells in addition to neurons produce 
endogenous GABA in vivo and in culture.44 Important for the biosynthesis of GABA is the 
expression of glutamic acid decarboxylase, which catalyzes the decarboxylation of glutamate to 
GABA, therefore producing the endogenous ligand. A cartoon of the existing components 
within a T cell is shown in Figure 42.  
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Figure 42. Cartoon image of the coexisting GABA, GABAA receptor, glutamic acid decarboxylase (GAD), 
and the GABA transporter 1 (GAT). 
Interleukin 2 (IL-2) is a protein that is known to play an important role in inflammation.45 
The lead compounds investigated in this work are seeking to treat diseases that result from 
inflammation, for example airway inflammation is a main symptom of asthma. Neuropathic 
pain is also closely tied to inflammation46 and is being investigated by MIDD researchers as a 
therapeutic target for benzodiazepines. It is of interest to know if a drug molecule can decrease 
inflammation therefore our research group employs an IL-2 ELISA assay to assess the protein 
expression in cell culture. Similarly, a calcium detection assay is employed to look at the 
aforementioned ion transport (as the GABAA receptor is an ion channel). The IL-2 ELISA assay is 
performed using a leukemia T cell line (Jurkat cells) and like the calcium assay GABA in addition 
to positive GABAAR modulators has an influence on the outcome of the assay. For this reason a 
method was developed to quantify the amount of GABA present in cell culture media. The cell 
culture media consists of among others of salts, amino acids, sugars and most importantly fetal 
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bovine serum. An efficient LC-MS method was developed to inject a sample with minimal front 
end preparation. However, GABA is a very small analyte with a limited hydrophobic character, 
which presents analytical challenges in the aforementioned LC-MS methods, which employ 
reversed phase separation by HPLC.  
The assays mentioned previously produced samples that could be analyzed with 
conventional reversed-phase material as stationary phases (for example, C18). These stationary 
phases contain hydrophobic groups, thus the analytes must display adequate hydrophobicity in 
order to interact with the stationary phase. For benzodiazepine-like GABAA receptor 
modulators of interest in this work, the majority of the compounds are of sufficient 
hydrophobic for this separation technique (as is typical for most drug compounds). However, 
analytes that are very polar are not compatible with conventional reversed-phase analyses 
because they cannot be retained on a reversed-phase analytical column. GABA for instance is 
not retained on a reversed phase column, making quantitation by LC-MS a challenge. One 
approach employed to quantify amino acids and other polar analytes include a front-end 
derivatization technique prior to LC-MS analysis. However, these strategies complicate the 
sample preparation, add extra cost for chemicals needed to create a derivative, and can result 
in non-specific derivatization of other compounds within the complex biological matrix to be 
analyzed. Therefore, when separation of more polar analytes is required, a different separation 
strategy called hydrophilic interaction liquid chromatography, or HILIC, can be employed. The 
advantage of this approach is the ability to maintain a simple sample preparation and direct 
sample analysis. Herein, we show that GABA is retained and quantifiable by HILIC 
chromatography. 
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For HILIC chromatography, the silica stationary phase particles are coated with a functional 
group designed to draw and retain water on the surface of the silica. One such example, which 
is employed in these analyses, is cross-linked diol groups for polar selectivity. This water layer 
facilitates the transfer of polar compounds from the mobile phase to the stationary phase, 
increasing the retention factor, whereas on a reversed phase column polar analytes would 
elute around the void time, making separations difficult. A representation of the stationary 
phase coated with an adsorbed water layer is shown in Figure 43. The water layer shifts the 
retention mechanism from being primarily hydrophobic interactions (as in a C18 column) or π-π 
interactions (as in a biphenyl column) to partitioning, rather, between the adsorbed water layer 
and the analyte in mobile phase. The mobile phase for HILIC separations is typically very similar 
to what is seen in reversed phase separations, largely organic with a small percentage of water 
(3-15%) to hydrate the stationary phase and adequately dissolve the polar analytes.  
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Figure 43. Cartoon representation of the polar stationary phase, the adsorbed water layer, and the 
partitioning mechanism of retention seen in HILIC separations (Image: Waters). 
 
5.2 Materials & Methods 
Jurkat cells were maintained in suspension in RPMI 1640 medium with L-glutamine (Thermo 
Fisher Scientific Inc., Rockford, IL) supplemented with 10% (v/v) fetal bovine serum. The cells 
were maintained in 5% CO2, 95% humidified air at 37 °C at an approximate density of 106 
cells/mL. Typically for the calcium assay, the Fluo-4 NW calcium assay kit (Life Technologies, 
Rockford, IL) is used for intracellular calcium measurements. Jurkat cells are collected, pelleted, 
and resuspended in Fluo-4 NW assay buffer at a final concentration of 5 × 106 cells/mL and 
dispensed into a 384 well plate. The plate is then analyzed as described previously. One 
microliter of test compound in DMSO or GABA in water is added to each well and incubated, to 
illustrate a dose response for either the compound, the endogenous ligand, or both.  
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Separation was performed on a Phenomenex Luna HILIC column (50 x 2.1 mm, 3 μm). The 
mobile phase was isocratic at 85% acetonitrile and 15% water. The mobile phase contained 5 
mM ammonium formate buffer, to control pH and aid in the ionization of analytes. Uracil was 
employed as an internal standard for the method because although it is not retained on a 
reversed phase column, and is generally used in RPLC to calculate void time. However, uracil is 
retained on a HILIC column.  
5.3 Results  
Previous assay results had illustrated an anomaly in the typical dose response curves of 
positive allosteric GABAAR modulators, in that GABA did not need to be added to the assay to 
activate the receptor. Ideally, this is a parameter of the assay which needs to be controlled, in 
order to generate an accurate dose response curve for comparison with other drug compounds 
of interest. Figure 44 shows the results of this assay with this anomaly, showing extremely 
similar dose response curves for the compound with or without the presence of GABA. 
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Figure 44. Calcium assay response of the lead asthma compound Xhe-III-74 acid in the presence of Jurkat 
cells illustrating the similarity of results with or without the addition of [1 mM] GABA. Data: Amanda 
Nieman. 
The assay shows a response difference between GABA and GABA dosed with compound, 
thus Xhe-III-74 acid is modulating [Ca]i. However, the addition of additional GABA did not 
change the response significantly, which can only be explained by endogenous GABA already 
present. Similar results were observed quantifying IL-2 protein by ELISA assay (Figure 455).   
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Figure 45. Results from the IL-2 ELISA assay from Jurkat cell extract showed a reduction of IL-2 in the 
presence of GABA and in XHE-III-74 acid and XHE-III-74 EE. However, no significant differences between 
the both compounds in the presence and absence of GABA were identified. (Data: Gloria Forkuo.) 
Thus, the amount of GABA in Jurkat cell media was quantified by HILIC-MS/MS. The cell 
density was 3x105 cells/ml and the cell media analyzed directly with a triple quadrupole LC-
MS/MS instrument. Standards of GABA were prepared in triplicate and diluted serially to 
generate the calibration curve.  
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Figure 46. Calibration curve for GABA determined by HILIC/MSMS. R square = 0.9902.  
 The average of three aliquots of Jurkat media was found to have 87.385 ppb GABA (or 
[0.847 μM]), with a relative standard deviation of 6.419%. The limit of quantification for this 
method was defined determined to be 24 ppb, which is consistent with other recently 
published articles quantifying the amount of GABA by HILIC methods.47 Although this method 
was a brief component within this presented work, it illustrates the importance of 
multidisciplinary knowledge within the drug discovery group.  
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CHAPTER 6. Pharmacokinetic Studies 
6.1 Introduction 
Pharmacokinetic (PK) assays are used in drug development to study the absorption, 
distribution, and elimination of a lead compound in vivo. This is done by quantifying the 
amount of drug in biological samples at sequential time points, and using that data to generate 
a pharmacokinetic curve. A plot of the general shape of a pharmacokinetic curve is shown in 
Figure 477.1 In this generic representation, samples would be taken at each arbitrary time unit 
and quantified using an analytical method, most commonly LC-MS/MS.  
 
Figure 47. General representation of a pharmacokinetic curve. 
Although PK data is traditionally generated from blood draws, the above curves can also be 
generated from quantified amounts of compounds extracted from target organs. For example, 
imidazobenzodiazepines in these studies are of interest to treat asthma, therefore it was 
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important to quantify the amount of compound in the lung, as the lung is the target organ.48 In 
addition, these compounds target GABAA receptors which are expressed in the brain, thus 
quantification of compound in brain tissue was important to estimate adverse side effects by 
the central nervous system. There are many known benzodiazepine compounds currently on 
the market (such as the 1,4-benzodiazepine drugs alprazolam, diazepam, and many others) for 
which the brain is the target organ. The primary difference between these known drugs and the 
lead compounds presented in this work (which contain the same core benzodiazepine 
structure) is the presence of key functional groups, attached to the core benzodiazepine 
scaffold. The functional groups determine whether or not the compound can cross the blood 
brain barrier and subsequently bind to GABAA receptors in the brain. In an effort to avoid any 
cognitive side effects for the asthma compounds, low amounts of compound are desired in the 
brain. Potential cognitive side effects are monitored using separate in vivo biological studies, 
both here at UWM as well as with collaborators at Columbia University. One such assay, for 
example, is the rotarod assay, in which mice are dosed with lead compound and tasked to run 
on a cylindrical rod. If the compound acts as a sedative, the mice will fall off of the rod.  To 
avoid cognitive side effects which may have a negative impact, like sedation, it is important to 
quantify the amount of compound in the brain.  
Benzodiazepines are known to be well absorbed by the GI tract after oral administration. 
They are highly protein bound and widely distributed in the body, typically accumulating in 
lipid-rich areas (such as the CNS and adipose tissue). The more lipophilic the compound, the 
higher the absorption rate and therefore the fastest the onset of clinical effects. There are 
several parameters of merit that are of importance in pharmacokinetic studies, including the 
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area under the pharmacokinetic curve (AUC), the time at which maximum compound is present 
in the blood or target organ (Tmax), the maximum concentration reached at that time (Cmax), 
and the rates at which the compound is both absorbed and eliminated. Similar to the 
microsome stability and brain homogenate assays a first-order elimination is assumed that 
enables the calculation of half-life based on the quantified amounts of drug in various tissue 
types. The half-life is the time interval required for the concentration of the drug to decrease by 
a factor of 0.5. As a general rule, a drug is said to be completely eliminated from the body after 
a period of five half-lives.2 The half-life expression is showed in Equation 10. 
Equation 10. The natural log of 2 divided by the elimination rate yields 
the elimination half-life. 
With regard to the concentration of compound in the blood, the compound can be 
bound to protein and therefore carried to the target organ, or it can be on the road to 
excretion. Therefore we are interested in the concentration as it relates to the protein bound 
drug. The rate of elimination as a function of time can be used to express the protein-bound 
concentration in a given sample as it relates to the initial protein-bound drug concentration, Cpo 
as shown in Equation 11. The non-protein bound fraction of the drug will not reach the target 
organ and generally will undergo excretion. 
Equation 11. 
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From these data, the rate of elimination can be shown as a first-order function of Cp. Clearance 
is determined from a concentration vs. time plot, which allows for the direct calculation of the 
area under the curve (AUC) with Equation 13. 
 Equation_12.
Equation 13. 
From the AUC, the clearance can be calculated from the original dose and the area under 
the curve, as shown in Equation 14.  
Equation 14. 
In addition to clearance, the volume of distribution is used to describe how a drug disperses 
throughout the body. An assessment of the total volume in which a drug will be distributed is a 
property of that drug, and is directly related to the elimination rate, the half-life, and the 
clearance for the drug.  
 Equation 15. 
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For the studies in this work, single-dose pharmacokinetic curves are generated by 
quantifying the amount of compound present in samples by LC-MS/MS. A generic 
representation of this curve is shown in Figure 488. 
 
Figure 48. General image of a pharmacokinetic curve resulting from oral or i.p. dosing schedule. 
However, orally delivered drugs must be absorbed from the digestive system first before 
they can enter the bloodstream (which is where Cp is determined).37 Therefore, from these 
curves we show both and absorption phase and an elimination phase. These relationships can 
also be described by Equation 17.  
 Equation 17. 
The variable F in the above equation is for bioavailability, which for an oral drug, depends 
on the resistance to first pass metabolism in the liver. The variable EH in Equation 18 refers to 
the hepatic extraction, therefore drugs with a high EH value have poor bioavailability.  
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Equation 18. 
In order to effectively plot all data points and calculate the parameters of particular 
interest, we have implemented a software program called PK Solutions from Summit Research 
Services.  
The analysis of bioanalytical samples presents challenges with regard to the elimination of 
matrix effects and species that interfere with analysis. These assays require highly sensitive 
analytical methods capable of achieving very low limits of detection for quantification. 
Obtaining low LOD and LOQ values can be achieved by increasing analyte signal, decreasing 
background noise, or both. One of the challenges in pharmacokinetics studies can result from 
the fact that complex biological matrices can create ion suppression issues in the mass 
spectrometer, due to many endogenous compounds that co-elute with analytes of interest. 
This is an inherently problematic shortcoming in LC-MS/MS analysis. Therefore, one of the 
method development goals is to maximize the amount of analyte available for analysis, as well 
as clean up the sample as much as possible to minimize matrix effects. PK studies require 
efficient chromatographic and sample preparation strategies, not only for the reasons listed 
above but also to facilitate the analysis of a large number of samples. The most commonly used 
sample preparation techniques are protein precipitation (with an organic solvent, essentially 
liquid-liquid extraction, or LLE) and solid phase extraction (SPE). Typically, extraction solvents 
for LLE are non-polar organic solvents that are different from the starting mobile phase of an LC 
method. Unfortunately, this disparity in polarity can lead to band broadening during 
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chromatographic separations. It can also create unpredicted changes in retention times. The 
most common way to remedy this issue in LLE sample preparation techniques is by evaporation 
of the extraction solvent followed by reconstitution in mobile phase. This reconstitution step 
allows for the flexibility to extract with any solvent desired rather than exclusively LC-MS 
friendly solvents.  
The other sample preparation approach, SPE, employs trapping the analytes in a 
hydrophobic sorbent (such as a C18) on a separate “trap” column. The samples are injected 
with an aqueous mobile phase to ensure that all of the hydrophobic analytes partition into the 
hydrophobic trap. Provided that the analytes are hydrophobic as well (as is the case with the 
imidazobenzodiazepines in these studies) they will partition preferentially into the trap column. 
Meanwhile, any water soluble proteins, peptides, salts, and contaminants will be flushed to 
waste. The analytes are then eluted from the SPE trap column with percentage of organic LC 
solvents and carried to the traditional analytical column. This process yields significantly cleaner 
chromatography given the absence of water-soluble interferences, which are endogenous to 
complex biological matrices. Herein, methods for both sample preparation strategies are 
presented, and results for several GABAA receptor modulators are presented.   
 
6.2 Experimental Procedure 
5-10 weeks old female Swiss Webster mice (Charles River Laboratory, WIL, MA) were used 
for the experiments. Mice were housed under pathogen-free conditions, under standard 
conditions of humidity, temperature and a controlled 12 hour light and dark cycle and had free 
access to food and water. All animal experiments conformed to the rules and regulations of the 
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University of Wisconsin, Milwaukee Institutional Animal Care and Use Committee (IACUC). 
Female Swiss Webster Mice were dosed by interperoniteal (i.p.) injection with vehicle or test 
compound formulated in DMSO/ propylene glycol/ PBS, 10:40:50, (v/v/v) and injected at a dose 
of 5 mg/kg. At 3, 10, 15, 20, 40 60, 90 and 120 minutes groups of mice were euthanized and 
blood (collected into heparinized tubes, 50 μL of 1 mg/mL heparin), lungs, and brain were 
harvested and the sample were stored in liquid nitrogen until analysis.  
Blood samples were thawed on wet ice, vortexed for 10 seconds, and a 100 μL aliquot 
was taken and added to 400 μL cold acetonitrile containing [20 nM] internal standard (HZ-166), 
which was of similar structure and had similar chemical properties. Samples were vortexed for 
30 seconds and centrifuged at 13,000 RPM for 3 minutes. The supernatant layer was then 
transferred to clean tubes and evaporated overnight. The residue was reconstituted with 300 
μL of mobile phase and spin-filtered through 0.22 μm nylon centrifugal filter units (Costar). 
After reconstitution, verapamil was added as a second internal standard to all samples as well 
as calibration standards. 5 μL of the sample was injected to the LC–MS/MS 8040.  
Brain and lung tissue samples were stored in liquid nitrogen prior to homogenization 
and extraction. Whole organs were thawed over ice, weighed, and homogenized directly into 
500 μL ACN containing an internal standard using either a Benchmark Scientific BeadBug 
Homogenizer with three 3.2mm stainless steel beads, or a handheld LabGen T2 homogenizer. 
Samples were homogenized for 30 seconds, centrifuged for 3 minutes at 13,000 RPM. This 
process was repeated for a total of three extractions. The supernatants were combined and 
prepared in the same manner as the blood samples for LC-MS/MS analysis.  
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High performance liquid chromatography (HPLC) was performed with Shimadzu Nexera 
X2 LC30AD series pumps (Shimadzu, Kyoto, Japan) that include a 20A5R degassing unit, SIL 
30AC autosampler and a 20A column oven. Analytes were separated by a Restek Ultra Biphenyl 
II column (2.1 mm × 50 mm, 5 μm particle size, Restek, California, US) under gradient elution at 
a flow rate of 0.6 mL/min. The mobile phase consisted of acetonitrile for the organic ‘B’ solvent 
and water for the aqueous ‘A’ solvent (both containing 0.1% formic acid). Time program: 10% B 
→ 99% B (3 min), hold at 99% B (3.75 min), return to 10% B (4 min), hold (4.5 min). Column 
Temperature: 50°C. 
Analytes were monitored under positive mode by Shimadzu 8040 triple quadrupole 
mass analyzer (Shimadzu, Kyoto, Japan) electrospray (ESI) and atmospheric pressure ionization 
(APCI) run in dual (DUIS) mode. The fragmentation transitions are monitored in multiple 
reaction monitoring (MRM) mode. Ion transition pairs for all analytes and collision energies are 
listed in Appendix A. Collision energy is optimized for each transition to obtain optimal 
sensitivity. The mass spectrometer was operated with the heat block temperature of 400°C, 
drying gas flow of 15 L/min, desolvation line temperature of 250°C, nebulizing gas flow of 1.5 
L/min, and both needle and interface voltages of 4.5 kV. The response acquisition was 
performed using LabSolutions software.  
 HZ-166 was chosen as an internal standard for the extraction method because it has 
similar chemical structure than the analyte and was therefore used to account for sample 
dilution, evaporation, and matrix effects. Verapamil was used as a second standard to monitor 
instrumental variations, both intra- and inter-batch. Stock solutions of all analytes were 
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prepared at concentration of 2 mg/mL separately in ACN and stored in a −20° C freezer, with 
the exception of carboxylic acid compounds, which were prepared in 80:20 ACN:water due to a 
lack of solubility in pure organic solvent. Intermediate working solutions of each were prepared 
by serial dilution with mobile phase (80:20, ACN:water with 0.1% formic acid). Calibration curve 
solutions were prepared at concentrations of 1, 5, 10, 15, 25, 50, 75, 100, and 150 nM on the 
same day as the analysis was performed.  
The intra-run/within-run validation was performed for concentrations of 10, 25 and 75 
nM with three replicates for each concentration. For separate validations, separate standard 
curves were newly prepared. The standard curves were fit by a linear regression and the 
validation samples were calculated back by the calibration curve of that day. The mean and the 
coefficient of variance (CV) were calculated accordingly. Accuracy was calculated by comparing 
calculated concentrations to corresponding nominal concentrations.  
Quantified concentrations were then analyzed by a separate software program to 
calculate pharmacokinetic parameter of merit. These parameters were calculated with PK 
solutions software 2.0 and fitted to the following equation: c = A•e-at + B•e-bt + C•e-ct . Due to 
the rapid absorption, two phases C = A•e-at + B•e-bt were sufficient to describe the 
pharmacokinetic curve: distribution/absorption phase and elimination phase. 
 In an effort to increase throughput and decrease sample handling time, blood samples 
were analyzed in parallel using an on-line solid phase extraction setup. Whole blood samples 
were diluted 4x into acetonitrile and filtered with push filter vials (Thompson Instrument 
Company, Oceanside CA) and placed directly into the autosampler for analysis by LC-MS/MS. 
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Analytes were loaded onto a ‘trap’ column (Strata-X column, Phenomenex, Torrence CA) with 
water at a flow rate of 0.1 mL/min. This is done using a third pump that is separate from the 
two traditional binary HPLC pumps. The instrument is plumbed using two valves to change the 
direction of the flow, which enables the binary pumps to elute the analytes from the trap 
column to the analytical column (as shown in Figure 49). Polar compounds from the blood 
samples such as small proteins or peptides will not be retained on the trap, and therefore will 
stay in the water phase during the loading process. The HPLC mobile phase begins the gradient 
method described above after the analytes have been given 3 minutes to load onto the trap 
column, and then conventional reversed phase LC-MS/MS analysis occurs as described above. 
Although the on-line SPE method requires additional analysis time on the instrument, it allows 
for a great decrease in sample handling time, as there is no need for manual protein 
precipitation with acetonitrile followed by evaporation and reconstitution in mobile phase.  
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Figure 49. Schematic of the on-line solid phase extraction and HPLC system, featuring four pumps, three 
degassing units, two rotation valves, and an autosampler. Pumps A and B are typical gradient pumps for 
HPLC, pump C is an HPLC pump for loading the trap column, and pump D is an extra pump for flushing 
lines to waste. The directionality pictured above illustrates the valves in load position. This directionality 
is reversed to send the eluate from the trap column to the analytical column.  
 
6.3 Results 
The initial development for the homogenization and extraction methods were applied 
for the extraction of analyte from biological samples sent from the Emala group at Columbia 
University. The initial lead compound, Xhe-III-74, was dosed via nebulized treatment to twelve 
C57/BL6 mice using a 12.5 mM solution of lead compound with 12.5 mM diazepam in 50:50 
ethanol:water. This initial distribution study aimed to identify whether or not the lead 
compound was seen in various tissue types: lung, liver, brain, and also blood plasma. Before 
attempting a full pharmacokinetic assessment, a method was needed to quantify these 
compounds in various biological samples.  
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Samples were weighed by difference into a 50 mL plastic conical tube. The tissue 
samples were homogenized with twice the amount of water. The homogenizer barrel was 
rinsed with two 650 μL portions of water, and the rinses were added to the mixture. The total 
solution was extracted four times with 6 mL of diethyl ether (this volume was chosen because it 
was approximately double the volume of the homogenate mixture). The ether layers were 
combined and evaporated to dryness in a round bottom flask. The analyte was reconstituted in 
5 mL methanol and sonicated to ensure all compound was dissolved. 1 mL of the analyte 
solution in methanol was spiked with HZ-166 as an internal standard at [20 ug/mL] and 
quantified on the triple quadrupole LC-MS 8040. Samples were ionized in DUIS mode, with 1.5 
L/min nebulizing gas, 250° C desolvation line temperature, 400° C heat block. Drying gas flow 
was 15 L/min. Analysis was completed with a method run time of 4.5 minutes with a 
methanol/water gradient containing 0.1% formic acid in the mobile phase. Gradient 
parameters: 10% B to 99% B (3 min), hold at 99% B (3.75 min), return to 10% (4 min), hold for 
30 seconds; flow rate of 0.6 mL/min. Column was a Restek Ultra biphenyl column, 3 μm, 100 x 
2.1 mm (with a 10 x 2.1 mm guard column). Retention times seen in this method were 2.8 
minutes for HZ-166, 3.1 minutes for Xhe-III-74, and 2.9 minutes for Diazepam. Results for this 
quantification are seen below in Figure 500. 
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Figure 50. Results of initial compound extraction study. 
Although the standard deviation bars for this experiment were much higher than 
desired, the main conclusion that can be drawn from this distribution study is that Xhe-III-74 is 
better absorbed than diazepam, especially in the brain. This is interesting because diazepam is 
known to cross the BBB and act upon GABAA receptors in the brain (the antidepressant Valium). 
However, it is also well known that diazepam is actually a pro-drug and is metabolized to 
nordiazepam, an active metabolite that is also able to pass the BBB. This metabolism is shown 
in Figure 511.  
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Figure 51. Diazepam and its active metabolite, nordiazepam. 
Because the triple quad detects compounds by mass it was necessary to develop an 
additional LC-MS/MS method to detect nordiazepam. Thus, the concentrations of nordiazepam 
were quantified and combined with the concentrations for diazepam to create Figure 522.   
 
Figure 52. Modified graph including the quantification of diazepam and nordiazepam (denoted DzNz for 
both compounds together). 
The comparison between Figure 50 and Figure 52 showed a small increase of the 
identified amounts of diazepam and nordiazepam. However, the distribution of XHE-III-74 is still 
superior to that that of diazepam.   
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Although this method was very thorough and was able to yield over 90% recovery via 
liquid-liquid extraction, the volume of organic solvent consumed was considerable. In addition 
to the cost of the solvent, this procedure must be performed in a fume hood due to the fumes 
of diethyl ether. Therefore, this method was not appropriate for high-throughput quantification 
for a large number of samples.  
In an effort to miniaturize this method, tissue samples were transferred to flat bottom 2 
mL tubes as opposed to 50 mL conical tubes. The tissue samples were then homogenized 
directly with organic solvent, as opposed to being homogenized in water and then extracted 
with organic solvent. This in essence creates a form of solid-liquid extraction, as the solid organ 
is homogenized with the liquid organic solvent. An internal standard of similar structure was 
spiked into the organic solvent prior to homogenization (e.g. HZ-166 in acetonitrile). These 
procedural changes allow for a significant decrease in solvent usage as well as a decrease in use 
of consumable materials (50 mL plastic tubes). The transfer of these samples from large conical 
tubes to smaller Eppendorf tubes also allows for the use of multichannel pipettes, which is 
helpful when preparing a large number of samples, to dispense the homogenization solvent 
with internal standard. It is also noteworthy that the large surface area of the 50 mL conical 
tube creates room for transfer error, as there is more solvent being transferred which requires 
multiple aspirations with a pipette.  
The first in vivo study completed with the miniaturized procedure was Xhe-III-74 Ethyl 
Ester. The compound was dosed by IP injection as described above. Xhe-III-74 Ethyl Ester was 
quantified in brain, lung, and blood samples, as shown in Figure 533.  
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Figure 53. Pharmacokinetic analysis of Xhe-III-74 Ethyl Ester.  
Table 5. Pharmacokinetic parameters of interest for the PK study of the Xhe-III-74 Ethyl Ester. 
Figure of Merit Blood Lung Brain 
Cmax (ng/ml) 216.9 120.7 84.8 
Tmax (min) 10 3 40 
AUC (ng*min/ml) 5737.0 3358.0 4516.0 
T1/2,E (min) 16.3 17.6 22.9 
T1/2,D (min) 26.6 2.2 36.7 
 Although Xhe-III-74 Ethyl Ester is rapidly absorbed and distributed, the concentrations 
seen in the brain are higher than desired for an asthma lead compound. Because hydrolyzed 
products are commonly seen in first pass metabolism, a carboxylic acid product was 
hypothesized to be created in vivo for this compound, as seen in Figure 544. The original 
samples that were dosed with the Xhe-III-74 Ethyl Ester compound were then re-quantified in 
search of the acid analog.  
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Figure 54. Conversion of Xhe-III-74 Ethyl Ester to the Xhe-III-74 Acid by hydrolysis in vivo. 
 
Figure 55. Pharmacokinetic curve for the Xhe-III-74 Acid in brain, lung, and blood samples. The animals 
were originally dosed with the Xhe-III-74 Ethyl Ester, therefore this acid compound is a metabolite. 
Table 6. Pharmacokinetic data for the acid metabolite of the Xhe-III-74 Ethyl Ester. nd indicates not 
determined due to the compound concentration being less than the lower limit of quantification. 
PK Parameters Blood Lung Brain 
Cmax (ng/ml) 102.3 <LLOQ <LLOQ 
Tmax (min) 10 nd nd 
AUC (ng*min/ml) 4282.3 nd nd 
T1/2,E (min) 11.6 nd nd 
T1/2,D (min) 2.8 nd nd 
 As the PK curve shows, the acid compound is not seen in the lung or the brain in any 
appreciable amount. It is also noteworthy that the AUC for the acid metabolite is very similar to 
the AUC for the Ethyl Ester compound, illustrating an equally effective distribution. Therefore, 
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the next logical step was to dose the mice directly with Xhe-III-74 acid, as opposed to rely on in 
vivo metabolism. This data is presented in Figure 566. 
 
Figure 56. Pharmacokinetic study for the Xhe-III-74 acid analog, dosed in the same manner as the Xhe-
III-74 Ethyl Ester. 
 Xhe-III-74 Ethyl Ester acid displayed good distribution in the blood and lung, as well as a 
lack of absorption in the brain. However, the compound was cleared or metabolized very 
rapidly from both the blood and the lung, so although it appears to have a fast onset the 
clearance is too rapid for a good asthma drug. The goal following this PK study was to screen 
additional compounds to identify a compound that does not cross the BBB and is cleared 
slowly.  
An inherent challenge presented by thorough in vivo studies is the immense time it 
takes to procure samples and the number of mice. Therefore it is difficult to screen many 
compounds with this method. In addition, the sample preparation as described above is time-
consuming. Although the miniaturization of this method was helpful for the throughput of 
samples as compared to LLE with diethyl ether, the manual homogenization step with the hand-
held homogenizer is a bottleneck step in and of itself, as the barrel must be thoroughly cleaned 
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between samples to avoid cross contamination. To eliminate this bottleneck issue and 
eliminate the risk of cross contamination between samples, several automated bead-based 
homogenizers were tested to investigate if the manual homogenizer could be eliminated.  
The Omni BeadRuptor is a beadmill that uses ceramic, metal, glass, garnet, or carbide 
beads for homogenizing 24 samples simultaneously. The BeadBug is a much lower power tool 
that uses zirconium or steel beads to homogenize 3 samples simultaneously. Several bead types 
were tested first with the BeadBug, as this was a relatively inexpensive tool (Figures 57 and 58).  
 
Figure 57. Brain extractions using the BeadBug tool. Figure 58. Lung extractions using the BeadBug. 
The zirconium beads were not strong enough to homogenize the lung tissue, therefore 
they were excluded as an option. Although the garnet and ceramic beads were able to 
homogenize the lung and brain tissue, the stainless steel beads were found to have a greater 
percentage of compound extracted within the first extraction. Therefore the stainless steel 
beads were chosen for future investigation. The Omni BeadRuptor was borrowed from Thermo 
Fisher Scientific for testing, with stainless steel beads used as the homogenization medium. The 
BeadRuptor yielded similar results to the BeadBug.   
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Figure 59. Homogenization methods overall comparison. 
Although the bead homogenization tools appeared to yield higher extraction results in 
the first extraction, ultimately a second extraction is still required to achieve greater than 90% 
extraction efficiency. Therefore, there is no significant difference between the bead-based 
homogenizers and the manual homogenizer. The main advantage that the bead tools provide is 
that they eliminate cross contamination between samples. However, the time to load the tubes 
and beads, and then recover the beads, does not actually decrease the sample preparation 
time. This added time would be worth it if this method was able to yield close to 100% recovery 
in one extraction, but this is not this case. In addition, these tools create an added cost in the 
beads, the specialized tubes, and the instruments themselves. Therefore we proceeded with 
hand-held homogenization at this time. 
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The liquid-liquid extraction method as listed previously is an inexpensive, robust, and 
uncomplicated method that is being used by several MIDD members. However, for the analysis 
of blood samples, an on-line solid phase extraction method was also tested. The advantage of 
this method for blood samples is the “dilute and shoot” capability provided. The method 
utilized the reversed phase cartridge to trap the analytes, and then they were eluted from the 
trap with the HPLC mobile phase. Figure 611 illustrates the comparison between both methods 
using samples for a PK study with MRS-01-66 (Figure 60).   
 
 
Figure 60. Structure for MRS-01-66, the dimethyl amide analog to Xhe-III-74. 
 
Figure 61 SPE vs. LLE data for blood samples, from the PK study of MRS-01-66. The variances seen are 
not statistically different. The means are only statistically different at the end time points (60, 90, 240 
minutes), which are at quantities <LLOQ. 
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That the two methods (SPE vs. LLE) are not statistically different and either method is 
acceptable for the analysis of whole blood samples on the triple quadrupole LC-MS/MS 
instrument. Quantified amounts were compared at each time point first with the two-tailed t 
test, and then with the f test, to illustrate no significant differences in both the means as well as 
the variances for the measurements. Thus, SPE and LLE methods yield very similar results. 
However, the SPE cannot be used for whole tissue samples because the samples cannot be 
injected, as solids, onto the LC-MS instrument.  
Our collaborators in the Cook group have synthesized the dimethyl amide compound 
MRS-I-66 to explore the differences between esters and amides for the imidazobenzodiazepine 
scaffold. As it is the case with the Xhe-III-74 Ethyl Ester, such compounds might hydrolyze to the 
corresponding acid. We observed in the microsome stability assay that esters and amides with 
longer and more branched carbon chains are metabolically less stable than their short carbon 
chain analogs. The result of the PK analysis for MRS-I-66 is depicted in Figure 622.   
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Figure 62. PK graph for the dimethyl amide compound.32 
Table 7. PK results for MRS-01-66 
Figure of Merit Blood Brain Lung 
Cmax (ng/g) 691 123 30 
Tmax (min) 3 10 3 
AUC (ng*min/ml) 6205 2701 764 
T1/2,E (min) 8.8 10.3 11.7 
Erate (min-1) 0.078 0.067 0.059 
 
Interestingly, MRS-01-66 displayed a rapid onset and also a rapid clearance. The amount 
of compound found in the lung, however, was far less at 30 ng/g. For these reasons, the MRS-
01-66 compound was not pursued as the primary lead compound for the asthma project.  
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3.2 Results for GLO1 Inhibitors 
Methylglyoxal is a non-enzymatic side product of glycolysis, catalyzed by a cytosolic 
enzyme, GLO1.49 The compound is inversely proportional to the enzymatic activity of GLO1, and 
has been shown in primary neuronal cultures to act as a competitive partial agonist for the 
GABAA receptor.50 An overexpression of this enzyme in mice has been shown previously to 
increase symptoms of anxiety and depression, but when dosed with methylglyoxal or a direct 
inhibitor to GLO1, these symptoms were decreased.49a Therefore, we investigated the potential 
of GLO1 inhibitors as antidepressants.51 Mice were dosed with i.p. injection as described above, 
and the samples prepared in the same manner as the compounds for the asthma project (LLE 
for the blood samples and manual homogenization for the tissues).   
Initially, the analyte pursued for detection in this study was the original GLO1 inhibitor 
pBBG, shown in Figure 633. However, the compound was not found in the blood samples by LC-
MS/MS analysis. Employing a similar strategy as above, we searched for a metabolite. Although 
the parent compound was not identified in the samples, the diacid metabolite was identified 
and quantified. The structure for this metabolic transition is illustrated in Figure 633. This 
metabolite was produced in vivo by hydrolysis.   
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Figure 63. Transition of pBBG compound into the diacid analog, proposed to occur in vivo. 
 
Figure 64. PK graphs for pBBG diacid and MeGFN in the brain.  
Table 8. Calculated PK parameters for two GLO1 inhibitor in the brain.  
 
The published results for the GLO1 project show the potential to produce fast acting 
antidepressant effects. The most straightforward explanation for the observed antidepressant-
like effects is that GLO1 inhibition increases MG concentrations. MG is a competitive partial 
agonist at GABAA receptors, and depression is associated with reductions in cerebrospinal fluid 
GABA levels as well as the number of GABAA receptors in cortical regions. In addition, chronic 
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antidepressant treatment correlates with an increase in GABA, supporting a potential role for 
GABAergic signaling in depression. The effects of GLO1 inhibitors on GABAergic signaling is 
distinct from any other GABAAR-acting compounds (such as benzodiazepines like alprazolam). 
MG acts as a competitive partial agonist at GABAA receptors, thus modulation of MG 
concentrations by GLO1 inhibitors may have different effects as compared to other GABAAR-
acting compounds.  
Previous studies have shown that genetic and pharmacological GLO1 inhibition, as well as MG 
administration, are anxiolytic, have anti-seizure effects and reduce ethanol consumption. The 
current results show that GLO1 inhibition might provide a unique strategy for treating 
depression with comorbid anxiety, epilepsy or alcohol use disorders, which would constitute a 
unique class of therapeutic compounds and would address an urgent need, given the high 
comorbidity of these disorders. Our findings suggest that modulation of GABAAR signaling may 
be a promising approach for the development of fast-acting antidepressants. 
 
6.4 Conclusions 
The importance of high-throughput analyses in drug discovery cannot be overstated. In 
an effort to speed up the sample preparation process as well as increase reproducibility, several 
homogenization methods were compared, several extraction methods were tested, and every 
opportunity to exploit rapid analyses was taken advantage of for these studies. Although the 
stainless steel bed homogenization method was able to yield comparable results to the manual 
homogenizer, the added cost of materials and equivalent sample preparation time did not 
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make this an advantageous option. However, the miniaturized extraction method with 
acetonitrile or methanol employed as the extraction solvent is sufficient for our analyses, as the 
analytes quantified in this work are all soluble in one or both of those solvents. Thus, the need 
for diethyl ether is eliminated. In addition, the on-line solid phase extraction continues to be 
implemented for studies within the MIDD due to increased purity of the sample and decreased 
sample preparation time for liquid matrices.  We have created the capability for the MIDD to 
establish a full pharmacokinetic profile for any lead compound of interest, and this assay has 
been repeated multiple times for various compounds to qualify drug candidates for further 
testing. If additional funding becomes available in the future, the Omni Bead Ruptor 24 could 
be re-visited as an option for tissue homogenates, including tissues other than brain and lung 
such as liver, kidney, small intestine, or any other pertinent organs important to drug discovery 
projects. The utility of solid-phase extraction can also be employed in an off-line manner, with 
96 or 364 well plates. This could be employed for metabolomics studies on the IT-TOF, which 
does not have an on-line solid phase extraction setup. It would be interesting not only to 
quantify the parent compound from drugs dosed in pharmacokinetic studies, but also to 
identify new metabolites in various tissue types.  
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CHAPTER 7. MALDI imaging mass spectrometry (MALDI IMS) 
7.1 Introduction 
Matrix assisted laser desorption ionization (MALDI) mass spectrometry had been widely 
implemented as a method to investigate large biomolecules, notably proteins and peptides that 
are too large to be analyzed with conventional LC-MS instruments. For example, a protein with 
a mass of tens of kilodaltons is far too large to be analyzed by a quadrupole mass analyzer 
(which typically has a maximum around 5,000 m/z with a reasonable scanning speed) without 
first being digested into small peptides by an enzyme such as trypsin. In the last decade, MALDI-
MS has come to the forefront in small molecule analyses, particularly as a method to analyze 
drugs or other small molecules in complex biological samples, such as whole cells and tissue 
sections without using extraction procedures. MALDI-MS also shows promise in diagnostic 
imaging (MALDI IMS), potentially identifying and localizing markers for diseases like cancer.52 
One distinct advantage of MALDI IMS as an imaging tool is that it is a label-free all-
encompassing technique, which doesn’t require antibodies or expensive and hazardous 
radiolabels. MALDI IMS has diverse application to many different analyte types and research 
areas, including but not limited to the study of new and existing proteins, peptides, nucleic 
acids, small molecules, and even polymers.53 Herein, we present a method developed to image 
drug compounds in tissue slices, employing collision induced dissociation to identify 
compounds of interest based on known fragmentation patterns. The mass detector employed 
for MALDI IMS is a Dual Time of Flight (TOF) analyzer with a collision cell that enables increased 
specificity with the generation of daughter ions (Figure 65).  
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Figure 65. Shimadzu 7090 MALDI-TOF/TOF instrument schematic. 
The instrument used in this work employs a 2kHz UV laser (355 nm) for ionization. The 
instrument is also equipped with a dual wire-grid ion gate, to gate species that may be close ion 
nominal mass, and produce distinct fragment ion spectra. High mass resolutions (10,000 
FHWM) are achieved by a combination of pulsed extraction, the ion optics, and axial spatial 
distribution focusing. When employing MSMS mode, the ions enter a collision cell at 20keV, 
which is a high-energy collision induced dissociation method with helium as the collision gas. 
The instrument is also capable of fragmenting ions in a low-energy manner. In this variation, 
the collision gas is not used, and so the ions detected are the result of spontaneous metastable 
decay of the precursor. The two differing fragmentation methods generate different fragments 
which can garner useful information about the analytes (for example, peptide side-chain and 
lipid backbone fragments will only be generated by high-energy CID). 
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In Matrix-Assisted Laser Desorption Ionization (MALDI), a low molecular weight matrix is 
mixed with the sample and allowed to crystallize. The crystalline matrix absorbs UV energy 
from the laser, and also aids to ionize the analytes (hence the term, matrix-assisted).  There are 
many matrix options commercially available, however, the matrix selections chosen for this 
work are common for small molecule analyses.  
Matrix selections: 
 CHCA (α-cyano-4-hydroxycinnamic acid) 
  DHB (2,5-dihydroxybenzoic acid) 
DHA (2,5-dihydroxyacetophenone) 
 
The MALDI technique is based on laser irradiation, which induces desorption and 
ionization of the analyte of interest as a molecular species ([M+1] or [M-1]).   
MALDI IMS generates an ion density map or “heat map” in which more brightly 
appearing areas indicate a higher abundancy of a specific ion that particular location. 
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Therefore, the technology gives us valuable information regarding the spatial distribution e.g. a 
drug distribution in a particular tissue. The spatial resolution in MALDI IMS is dependent on the 
laser beam focus (including diameter and space between laser shots), the size of the crystal 
matrix, and the diffusion or delocalization of analytes during the sample preparation process.54 
The localization of compounds in a specific target tissue has valuable information in regards to 
the interaction of drug and protein target.55 Pharmacokinetic studies have shown that 
imidazobenzodiazepines distribute in the lungs (which is the target organ for our asthma 
project) by quantification of lung homogenates using LC-MS/MS. Herein, a method is presented 
to image the localization of imidazobenzodiazepines in mouse lung tissue slices.  
Although the ion density map generates valuable information regarding localization of 
ions of interest, the information can be enhanced when combining it with histological stains. 
Sections can be taken in serial fashion, thereby making the differences between the sections 
equivalent only to the thickness of the tissue section (for example, 12 micrometers). The 
histological stain gives morphological information about the tissue, which can aid in the 
explanation of why certain areas of the MALDI image may show high or low ion density. For 
example, if there is a large gap in the ion density map of the lung, the histological stain might 
show the absence of tissue such as a large airway or blood vessel. The hematoxylin and eosin 
stain will show the nuclear contents as blue-purple, and red blood cells, non-nuclei, and 
extracellular material will be pink. An example of the H&E stain is presented in Figure 66, 
showing an airway for mouse lung tissue sliced at 12 µm thickness. 
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Figure 66. H&E stain of mouse lung, showing the airway morphology. 
In order to visualize the target protein of a small molecule, immunohistochemistry can 
be employed using specific antibodies in conjunction with enzymatic or fluorescent detection. 
Indirect immunohistochemistry methods employ an unlabeled primary antibody to bind to the 
target antigen, in this case the α5 subunit of the GABAA receptor. A labeled secondary antibody 
interacts specifically with the primary antibody and enables detection of the receptor. Two 
labels were used to image the alpha 5 subunit of the GABAA receptor. Firstly, horseradish 
peroxidase protein (HRP), which is an enzyme that catalyzes the oxidation of specific substrates 
in the presence of hydrogen peroxide, resulting in a colored product. The substrate used for 
HRP was 3,3’-diaminobenzidine (DAB). DAB reacts with HRP in the presence of peroxide to yield 
an insoluble brown-colored phenazine polymer at locations where peroxidase-conjugated 
antibodies are bound to the tissue.  
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Figure 67. Cartoon of the reaction of horseradish peroxidase and DAB substrate to produce brown 
coloration in tissue stains. (Image: AbCam.) 
 Secondly, a fluorescent small molecule can be attached to the secondary antibody, and 
its fluorescence signal measured rather than visualizing the product on an enzymatic reaction. 
Fluorescein and Cy5, both very common fluorescent dyes used for the immunohistochemistry, 
were attempted for the immunofluorescence stain of the α5 receptor.  
 
Figure 68. Dyes used for immunofluorescence. FITC shows excitation and emission at 495 nm 
and 519 nm, respectively, and Cy5 Ex: 650nm, Em: 667nm.  
4,6-Diamidino-2-phenylindole (DAPI) was used to stain the nuclei of all cell Figure 69.  
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Figure 69. 4,6-Diamidino-2-phenylindole DAPI Ex: 358 nm, Em: 461 nm.   
 DAPI is a di-cation at physiological pH and becomes strongly fluorescent when bound to 
double-stranded DNA in the nucleus. The interaction with RNA is weaker thus the resulting 
fluorescence is less pronounced for RNA.  
The combination of MALDI-MS, H&E stain and immunohistochemistry can illustrates 
valuable information of how a compound is distributed in vivo. MALDI IMS can also be used to 
investigate metabolites generated through xenobiotic metabolic processes in the animal, as 
well as adducts generated by the mass spectrometer itself. Investigative results will be 
presented herein. 
 
7.2 Materials and Methods 
7.2.1 MALDI IMS  
MALDI matricies were purchased from Sigma Aldrich (St. Louis, MO, USA): α-Cyano-4-
hydroxycinnamic acid #70990; 2,5-dihydroxybenzoic acid #85707, 2,6-Dihydroxyacetophenone, 
#37468. MALDI calibration kit was also purchased from Sigma Aldrich (ProteoMass™ Peptide 
and Protein MALDI-MS Calibration Kit, MSCAL) and used for calibrations according to the 
package insert. Metal slides were purchased from Shimadzu Scientific (Japan).  
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Swiss Webster female mice were dosed with 25 mg/kg compound via oral gavage and 
sacrificed as according to the Tmax determined in previous PK studies. Mice were sacrificed by 
CO2 and spinal cord dislocation (IACUC protocol 16-17 #25). Tissues were procured immediately 
and exposed to dry ice vapor for five seconds followed by dry ice to freeze. Lungs were stored 
at -80°C until cryosectioning with a Leica cryostat. Just before cryosectioning, lungs were 
allowed to equilibrate to -20°C for 30 minutes. Lungs were sectioned at 20 micron thickness 
and thaw-mounted to metal slides. Slides were allowed to come to room temperature in a 
desiccator for 5 minutes, gently rinsed with water containing 0.1% TFA to remove salts, and 
allowed to dry again at room temperature before matrix application. Matrix was applied using a 
manual spray coating method with a TLC sprayer. 10 mL of matrix solution at 50 mg/mL was 
passed at 3 psi using nitrogen gas. Matrix was allowed to dry fully between passes. The spray is 
wet enough to extract analytes from the solid sample into the matrix, but dry enough to rapidly 
crystallize and prevent delocalization of the analytes’ spatial locations. The TLC sprayer is slowly 
passed approximately 12 inches in front of the sample plate, which hangs vertically in the fume 
hood. Each pass applies a small amount of matrix, therefore the passes are repeated until all of 
the solution is used up and the samples are sufficiently coated.   
7.2.2 H&E stain  
Fresh frozen tissue sections were taken in serial fashion (to the sections used for MALDI IMS) at 
12 μm thickness and stored at -80°C prior to staining. Sections were rehydrated in the following 
sequence: 30s in 95% ethanol, 30s in 70% ethanol, 30s in Milli-Q water. Slides were stained in 
hematoxylin stain (VWR, 95057-844) for 1 minute, followed by rinsing in Milli-Q water for 3 
minutes, and again 30s in 70% EtOH and 30s in 95% EtOH. Sections were then stained for 30s in 
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eosin stain (VWR 95057-848), and subsequently cleared for 30s in 95% EtOH, 30s in 100% EtOH, 
and 2.5 min in histoclear clearing solution (VWR 64110-04), which is a substitute for the 
traditional clearing reagent xylene. After drying, 1 drop of Permount adhesive (VWR 100496-
550) was placed on each section and covered with a glass cover slip. Slides were allowed to dry 
overnight before viewing under light microscopy.  
7.2.3 Immunohistochemistry: 
Mouse lung sections were taken at 12 micron thickness in serial fashion to the slides for the 
MALDI and for H&E staining, and placed on glass microscope slides. Frozen section slides were 
stored at -80°C in a sealed slide box. Just before staining, slides were allowed to equilibrate to -
20°C. Slides were fixed for 10 minutes in cold 4% paraformaldehyde solution and allowed to 
warm to room temperature. Antigen retrieval was performed by placing the slides in 10 mM 
sodium citrate buffer at pH = 6.0 in a pressure cooker at 15 psi for 10 minutes. Slides were then 
rinsed with PBS and a PAP Pen was used to create wells for the liquid on the surface of the glass 
slides. Slides were subsequently washed with TBS Tween for 5 min, peroxidase suppressor 
(Thermo Fisher Scientific, 35000) for 15 min, and twice more with TBST for 5 minutes. The 
peroxidase suppressor reduces the background signals generated from endogenous 
horseradish peroxidase in the tissue. Slides were then washed with background sniper for 10 
minutes to block nonspecific staining resulting from the antibodies binding to proteins other 
than GABAARs. Slides were washed twice more with TBST before incubation with the primary 
antibody. Antibodies were diluted 1:100 and 1:250 with superblock T20 buffer as the diluent. 
The slides were incubated overnight in the 4 degree. Wet paper towels were placed inside the 
slide holder to retain moisture and prevent the glass slides from drying overnight.  
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Following overnight incubation, slides were washed three times with TBS Tween for 6 minutes. 
The secondary antibody was diluted in the same manner as the primary antibody and was 
applied to the slides at room temperature and allowed to incubate for 40 minutes. Slides were 
again washed three times with TBST for 6 minutes. Following the washes the chromogen DAB 
substrate, which was diluted 10-fold into peroxidase substrate buffer and applied to the slides 
for 6 minutes. Slides were washed with ddH2O for 5 min and counterstained with Hemotoxylin 
solution for 1.5 min to stain the nuclei. Slides were rinsed with ddH2O and dehydrated through 
4 changes of alcohol solutions (95%, 95%, 100% and 100%). Finally, slides were cleared in 3 
changes of histoclear and coverslipped using permount mounting solution. 
For the fluorescent immunohistochemistry stains, the same procedure was followed, except 
rather than fixing the tissue and performing antigen retrieval, which is necessary to preserve 
the tissue for an overnight incubation step, this step was omitted and the tissue was incubated 
rather for 1 hour at room temperature (with the primary antibody). Silane coated microscope 
slides (NC9968319, Fisher Scientific) were also implemented to improve the adherence of the 
tissue to the slides. The simplified procedure consisted of rehydration in PBS for ten minutes, 
PAP pen to create wells, blocking non-specific background staining with background sniper or 
5% animal serum, washing with PBS, application of the primary antibody with 60 minutes 
incubation, washing, application of the secondary antibody with 30 minutes incubation, 
washing, application of 1.5 μg/mL DAPI for 10 minutes, two final washes with TBST and 
coverslipping with Prolong Gold anti-fade reagent.  
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7.3 Results & Discussion 
The method development process for MALDI IMS is very involved, including optimization 
steps required at several stages: the in-vivo dosing of the animal, the sample preparation of the 
tissue, the matrix selection and deposition, instrument conditions, and finally, image resolution. 
The ADME property of a drug determines how a test animal processes a compound and which 
concentrations can be found in biological sample at a particular time point. For MALDI IMS, high 
tissue compound concentrations are necessary due it’s desorption process, which is 
significantly less sensitive than quantification of tissue extracts by triple quadrupole LC-MS/MS. 
The matrix application plays an important role in this. Typical matrix concentrations are 20-100 
mg/mL, which by far exceeds the expected concentration of the analyte. The large matrix 
concentrations in turn cause interferences in the TOF analyzer. Purification of the sample is 
challenging and often not seen in MALDI IMS, especially with small molecule imaging. Samples 
used for small molecule imaging experiments cannot undergo extensive washing steps, because 
the analytes can delocalize from their original location or be washed away completely. The 
introduction of high levels of matrix also presents challenges regarding signal suppression, 
which are enhanced as compared to typical LC-MS analysis. For the MALDI IMS experiments 
presented herein, a full pharmacokinetic profile of each compound was established first by LC-
MS/MS to determine the Tmax. In a separate experiment, dosed animals were sacrificed at that 
specific time point to ensure high compound concentrations.  
 The matrix deposition process is, in and of itself, a broad field of study in MALDI IMS. 
The most common methods employed are sublimation, spotting via micropipette or an 
automated liquid distribution system, and spray coating, which can be automated with a spray 
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instrument, or performed manually using a TLC sprayer or an artistic sprayer. The most rapid 
and cost effective option was determined to be manual spray coating.  
 Matrix selection for each compound presents another unique challenge for MALDI IMS 
because although one can easily optimize a matrix for pure compound by spotting the 
compound directly with various matrixes followed by analysis, the results may not translate to 
imaging experiments with tissue samples. One reason for this is that the matrix interferences 
presented by a complicated sample like a tissue slice cannot be predicted or adequately 
assessed beforehand. Therefore, the optimization of matrix selection needs to take place using 
actual tissue. It is ideal to take one tissue and serial section it so that the comparison of matrix 
choices are under comparable experimental conditions. An image of the workflow for the 
sample preparation prior to MALDI ISMS is shown in Figure 70. 
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Figure 70. MALDI IMS workflow. Images presented in this chapter were generated from a compound 
synthesized by Guanguan Li of the Cook research group. Pharmacokinetic study was performed 
previously by Revathi Kodali and Nick Zahn, as published previously.56 
 
7.3.1 MALDI IMS results using MS/MS mode 
Initial method development was performed on a manual spot of the analyte, for 
verification that the analyte is in fact ionized by MALDI. Manual spotting also allows us to 
ascertain the masses of fragments generated in MS/MS mode (similar to the method 
development process on LC-MS/MS instruments) prior to actual sample analysis. A table of 
fragments generated via both ionization methods is listed in appendix a. Figure 71 shows a 
typical spectrum for the MALDI in MS/MS mode for the SH-053-2’F-R-CH3 acid compound.  
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Figure 71. MALDI-MS/MS spectrum of the SH-053-2’F-R-CH3 acid spotted with DHB as the matrix.  
 Although generally speaking many of the same fragments are generated by collision 
induced dissociation in both MALDI-TOF/TOF and ESI-MS/MS, there can certainly be differences 
in fragmentation patterns.  Initial lung section images were generated based on the transition 
of m/z 360 [M+1] to m/z 316 fragment common to both ionization methods (Figure 72). 
 
Figure 72. Lung section imaged for the 360>316 transition in MALDI-MS/MS. MSI import 200-400 bin 
size 3, 5905 data points, 54.1843 MB, 62x74x51500 dpi and H&E stained serial tissue section.  
 
 The initial MALDI IMS image produced an unexpected result, showing what appears to 
be an outline of the lung tissue section. This raises concerns of validity for this experiment 
because we know this compound is localized in the lung and binds GABAAR alpha 5 receptors, 
which are believed to be located in the airway of the lung.48 Thus, the image above must be the 
product of either wrong sample preparation or wrong analysis.   
Another important sample preparation consideration is the limited options for purifying 
the sample. One such option is washing the tissue, in an attempt to de-salt the sample and 
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eliminate interferences. Without this step, the analyte was only detected around the edges of a 
tissue section of interest. However, with the addition of a gentle washing step, the analyte then 
appears throughout the tissue section, which more closely correlates with the target receptor 
in the tissue (Figure 73).   
 
Figure 73. Comparison of unwashed vs. washed lung tissue sections in MALDI IMS using the 360>316 
transition.  
The washing step improved the signal for SH-053-2’F-R-CH3 acid not only due to the 
removal of potential interferences, but also by removing SH-053-2’F-R-CH3 acid from the edge 
of the slice that may have been delocalized during the sample preparation process. The 
cryosectioning for the lung tissue sections was performed at -20°C. However, the matrix 
application was performed at room temperature. Therefore, before application of the matrix, it 
was necessary to equilibrate the slides from -20°C to RT. The issue presented is that taking a 
metal slide from a freezer and bringing it to room temperature results in condensation across 
the entire slide. As a water layer forms, the small droplets have the ability to move the analytes 
of interest from their original location, potentially leeching out of the tissue sample and onto 
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the slide. This coupled with fact that the tissue slice is a slightly raised on a rough surface 
compared to a smooth, flat metal slide, resulted in the formation of a ring of condensation 
around the edges of the tissue section. In attempts to avoid this condensation issue, slides are 
placed in a desiccator to equilibrate to temperature. This alone, however, did not solve the 
edging issue. Adding a washing step to uniformly remove all of the condensation prior to matrix 
application appears to solve the issue of the compound appearing only along the edges of the 
tissue section. Using this methods to other transitions of SH-053-2’F-R-CH3 acid were analyzed 
using serial tissue slices (Figure 74) 
 
Figure 74. Images of two lung tissue sections of SH-053-2’F-R-CH3 acid dosed mice at 360>283 m/z and 
360>301 m/z transition, respectively.  
The fragments imaged in Figure 74 are reproducible in imaging the SH-053-2’F-R-CH3 
acid, and are seen in every dosed tissue section. It is important to note that these masses are 
not present in tissue section prepared from vehicle dosed animals under the same 
experimental conditions, as illustrated in Figure 75.  
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Figure 75. Comparison of lung tissue from vehicle and SH-053-2’F-R-CH3 acid dosed mice. These sections 
were taken using the same MS/MS method 360>283 m/z. Both samples were prepared on the same day 
with the same matrix solution and application.  
 
Compared with the tissue from non-treated mice, SH-053-2’F-R-CH3 acid was present in the 
lungs and distributed throughout the tissue.  
 For any MS/MS technique, it is imperative that the method utilize reproducible 
fragmentation of the analyte, to ensure that the compound is identified correctly. This high 
level of specificity holds true for MALDI IMS, with the ability to distinguish the analyte from 
other compounds. The Shimadzu 7090 instrument also employs a reflectron after the flight 
tube, which is useful for the detection of low molecular weight analytes, as they can be difficult 
to separate in TOF analysis. These compounds travel very quickly down the flight tube impeding 
separation by time limited by the fight path. The reflectron enables additional separation by 
increasing the flight path. The instrument tuning varies when employing the reflectron in MS1 
mode vs. MS/MS mode. For larger masses, the tuning is set in linear mode. For small masses 
 114 
 
with no fragmentation, the tuning is set in reflectron mode. For small masses with 
fragmentation, the tuning is set in reflectron MS/MS mode. The parameters for each 
instrument mode are shown in Figure 77, linear mode, reflectron mode, and reflectron MS/MS 
mode. Although the parent compound can be detected using MS1 mode, the MS/MS 
capabilities increase this specificity and therefore yield a better spatial resolution for the 
location of the analyte (Figure 76).   
 
Figure 76. [M+1] ion image for the lead compound (SH-053-2’F-R-CH3 acid) in reflectron mode and 
fragmentation 360>282.932 m/z in reflectron MS/MS mode.  
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Figure 77. Tuning settings for the linear, reflectron, and reflectron MSMS modes of the MALDI-7090. 
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When the ion density map is compared with microscope images of stained tissue, the 
morphological information yielded by H&E stain allows for rationalization of patterns within the 
ion density map. In Figure 78 below, it can be seen that any sparse areas within ion density 
map, or “holes” where the compound is not present are actually a result of the serial section 
lacking tissue in that particular area. When viewing the ion density map alone, it may appear 
that the compound is not evenly distributed in the lung. However, when viewing the H&E stain 
in parallel, it is clear that this is not the case.  
 
Figure 78. Light microscope image of lung tissue stained with H&E (4x magnification) and MALDI IMS 
image of the daughter ion in a serial tissue section (transition 360>282.930).  
 MALDI IMS presents an additional unique challenge in that the sample preparation 
strategy employed for one analyte may not necessarily translate to another analyte. One 
example is compound GL-II-93. Initial images acquired presented the same challenges as SH-
053-2’F-R-CH3 acid, showing what appeared to be an outline of the tissue section, as opposed 
to consistent distribution throughout the lung section.  
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Figure 79. Two separate lung tissue sections imaged for GL-II-93 in reflectron MSMS mode, for the 
transition of the parent 416>357.  
 The GL-II-93 is structurally similar to SH-053-2’F-R-CH3 acid, having the same core 
imidazobenzodiazepine scaffold and pendant phenyl ring (Figure 80). However, there is a 
difference in electron density due to the variance in the functional groups present. Gl-II-93 has 
a bromine instead of an acetylene substituent.  Unfortunately, a simple washing step did not 
prove effective for Gl-II-93 to remove interferences and generate better images.  
 
Figure 80. Structure of GL-II-93 and SH-053-2’F-R-CH3 acid. 
 The solution for this particular sample preparation challenge lied in the selection of 
matrix. Although many application work with DHB, each analyte can cocrystallize and ionize 
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better or worse depending on the matrix selected. Shifting from DHB to DHAP showed a 
significant improvement in the image for GL-II-93 as seen in Figure 81. 
 
Figure 81. Images for GL-II-93 with dihydroxybenzoic acid (416>237), and with dihydroxyacetophenone 
(416 parent viewed in MSMS mode) as the matrix, respectively 
 Reproducible fragments were generated for GL-II-93 as well (Figure 82), although the 
ion density maps were not as strong as those seen for SH-053-2’F-R-CH3 acid. Figure 83 
illustrates a proposed fragmentation pattern seen for the analyte in both ESI-MS and MALDI-
MS.  
 119 
 
 
Figure 82. Fragment images for GL-II-93 for 416>331 and 416>370 transitions.  
 
Figure 83. Proposed fragmentation pattern for the GL II 93 compound, for the fragments imaged above.  
 An important consideration in any analytical method development is the efficiency of a 
method. In MALDI-IMS, the spatial resolution of the image can be increased based on the 
distance between spots the laser fires upon, as well as the diameter of the laser itself. All 
images above were taken at a spatial resolution of 100 micron, with a laser diameter of 100 
micron. However, the instrument is capable of smaller diameters for both spatial resolution and 
laser diameter. The image in Figure 84 shows the same experimental sample preparation as the 
images above, but with the spatial resolution and laser diameter both set to 50 micron instead 
of 100 micron.  
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Figure 84. GL-II-93 parent compound (416 m/z) at 50 micron resolution, for two lobes of lung tissue.  
The resolution is greatly improved with the 50 micron resolution and good distribution 
of GL-II-93 is detected throughout the tissue. However, the analysis time and data file size was 
also significantly larger. For the acquired image analysis above the analysis time doubled. 
Therefore it is important to determine if the information gained from a higher resolution (and 
longer lasting) experiment is really more significant than that of a lower resolution experiment. 
One does not necessarily need to keep the spatial resolution and laser diameter the same, 
however. It is possible to “oversample” and have a laser diameter larger than the diameter of 
the laser, therefore rastering across parts of the tissue twice and potentially ionizing even more 
sample. An example of this “oversampling” technique is shown with the images in Figure 85. 
The spatial resolution is decreased while the laser diameter is held constant. 
 121 
 
  
Figure 85. Samples imaged at 70 micron and 80 micron spatial resolution, respectively, with the laser 
diameter held at 100 micron. Left image is GL-II-93 416>373, right image is SH-053-2’F-R-CH3 acid 
360>283. H&E stain is also pictured at zero magnification, which correlates with the SH section. 
By moving the sample target a distance that is less than the diameter of the laser beam, 
image resolution is enhanced, as more of the sample is ablated. Ideally the MALDI matrix is 
applied sufficiently wet so that the analyte within the sample is incorporate into the matrix, but 
must dry rapidly enough to minimize migration within the tissue sample. In addition to this, 
complete ablation of the sample is desired, to consistently acquire the maximum amount of 
signal possible.57  
 
7.3.2 MALDI results in MS1 mode 
MALDI IMS can also be used as an investigative tool to gain insight into potential 
metabolites generated in vivo, since all of the samples imaged are from lungs of mice dosed 
with GL-II-93.  
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 In addition, to use MALDI IMS in the reflecton MS/MS mode, which results in high 
specificity towards an analyte of interest, the MS1 mode (linear mode) can be used to 
investigate adducts generated in vivo, or metabolites within the tissue sample. In reflectron 
MS/MS mode, ion gating only allows the parent mass (defined by a specified range) to be 
fragmented and analysis by the second flight tube. Therefore, adducts or metabolites that have 
a different mass will be exclude. The MS1 mode however, will enable the quantification of 
distinct masses defined by a specific mass range, such as in Figure 86, which depicts the mass of 
436 m/z which corresponds to GL-II-93 + Na+.    
 
Figure 86. The GL-II-93+Na+ imaged in a lung tissue section. 
Another strong ion 203 m/z was detected in the MS1 mode and quantified by MALDI 
IMS. This mass was absent in the lung tissue from non-treated mice thus it strongly suggest that 
it might be a metabolite of GL-II-93 (Figure 87).  
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Figure 87. Unknown metabolite at m/z 203. The top sections show the lung without and with washing to 
remove salt interferences. The bottom sections show this mass imaged in undosed lung tissue sections. 
 
Although the structure of the 203m/z ion is not known, it might be interesting to quantify it in 
PK samples to determine it’s occurrence in a time dependent manner. To confirm this 
compound as an metabolite of GL-II-93, it’s concentration should increased and then decreases 
in time similar to parent compound GL-II-93.  
 
7.3.3 Immunohistochemistry results 
The results of the immunohistochemistry experiment using a HRP conjugated secondary 
antibody for the α5 subunit or the GABAAR are depicted in Figure 88.   
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Figure 88. HRP stain of lung tissue section, with brown and blue colors.  
 
Figure 88 shows a light brown background stain and a more intensive brown stain for some of 
the lung tissue areas. Unfortunately, the blue counter stain of hematoxylin was difficult to 
distinguish from the brown tissue stain using a standard light microscopy. Therefore, a 
secondary antibody with a fluorescein tag was employed to improve the quality of the 
immunohistochemistry picture using fluorescence microscopy rather than light microscopy, 
which enables the decrease of background signals (Figure 89). For immunofluorescence, the 
tissue counterstain is imaged in a different channel than the antibody conjugate. Therefore the 
overlap issue is eliminated.  
Brown stain surrounding the 
airway, possibly the alpha 5 
GABAA receptor subunit  
 
Blueish Brown color as 
counterstain for general 
tissue 
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   Figure 89. Positively and negatively (without primary antibody for α5 GABAAR subunit) stained 
lung airways imaged with a FITC conjugated secondary antibody.  
  Although the positive image (left) appears brighter than the negative control, a better 
resolution is necessary to confirm staining of the α5 GABAAR subunit in lung tissue. These 
pictures were taken with an Evos AMG fluorescence microscope (Frick lab, Department of 
Chemistry & Biochemistry, UWM). However, while improving this procedure the imaging was 
transferred to a Nikon inverted fluorescence microscope (Steeber lab, Department of Biological 
Sciences, UWM) which provided significantly improved image quality. We also substituted the 
FITC conjugated secondary antibody for a Cy5 conjugated secondary antibody. The resulting 
images are shown in Figure 90.  
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Figure 90. Positively stained mouse airway sections, imaged with Cy5 fluorescence at 200x 
magnification.  
Staining for the α5 GABAAR subunit was clearly observed with relatively intense staining 
around the lung airways that consist of epithelial cells and smooth muscle cells. Although the 
Nikon microscope produces black and white images, the level of background and signal can be 
matched between samples for comparison. The images can also be colored after the fact, which 
can aid in the overlay of multiple images if necessary. A comparison between positive and 
negative staining is provided in Figure 91.    
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Figure 89. Mouse lung airways stained with the Cy5 probe at the alpha 5 receptor (positive staining and 
negative control). Image on the top represents a positive airway stain, original black and white color.The 
image presented on the left is the same as the previous figure, however the pseudocoloring 
functionality has been employed on the microscope to show the positive staining as a red color. 
Negative controls were conducted by omission of the primary antibody. 
In order to establish a comparison between positive and negative sections, it is desirable 
to compare similar morphologies. In this work, the airway is the morphology of specific interest. 
Therefore, during the imaging process, airways were first identified using a DAPI stain, to 
ensure that the morphologies being compared were correct ones. An example is given in Figure 
90.  
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Figure 90. DAPI stain of lung tissue, showing two airways.  
Once the morphology of the airway was identified, the tissue slice was imaged with fluorescent 
light to visualize the location of the α5 GABAAR subunit. The above immunological stains were 
taken from serial sections to the following, which was concurrently analyzed by MALDI IMS.  
 
Figure 91. Serial section of lung tissue imaged for the SH-053-2’F-R-CH3 acid. The IHC images in Error! 
Reference source not found. were taken from a serial section of this lung sample, indicating the 
presence of both the alpha 5 GABAAR subunit and SH-053-2’F-R-CH3 acid in the same lung.  
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 In addition, brain tissue was used as a positive control for the immunohistochemistry 
protocol because the expression of the alpha 5 GABAAR subunit has been reported for the 
brain.58  
 
Figure 92. Mouse brain sections stained for alpha 5 GABAAR subunit. The left section was a negative 
control by omission of the primary antibody. For the right image the primary antibody was added.  
 Finally all four imaging techniques (immunohistochemistry, MALDI IMS, H&E and 
confocal microscopy) were combined from four consecutive slices from a mouse lung (Figure 
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95). 
 
Figure 93. Mouse lung serial sections including overall ion density map, correlating H&E stain at 100x 
magnification, and Cy5 IHC at 200x magnification.  
These images show good correlation between the location of the compound of interest in the 
MALDI IMS data, the IHC tissue stain, and the H&E stained tissue, all taken in serial fashion. The 
current obstacle with this multi-modal comparison lies in the varying magnification levels that 
generate optimum data for each method. While H&E stains can be viewed at any magnification, 
the immunofluorescence is only seen when the magnification is at 200x. The fluorescence 
signal can be somewhat visualized at 100x, but the resolution makes localization difficult. The 
MALDI IMS image resolution can be increased and therefore “zoomed in” if the images were 
taken with a higher spatial resolution image (the instrument can go as low as 10 μm), however 
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at the time of this work, the instrument was experiencing technical limitations which made 
imaging experiments lower than 50 μm impossible. This issue is currently being resolved by the 
MIDD. 
7.4 Conclusions 
We have shown the ability to image small molecules in different tissue samples by MALDI-
MS/MS, which is a technique on the forefront of drug discovery today. The 7090 Shimadzu 
instrument, however, has limitations with regard to the quality of images that can be 
generated. Major limitations are regarding the laser diameter and spatial resolution. An 
important compromise was made for imaging experiments, as the more data points acquired 
equates to longer analysis time. The image resolution can actually be predictively increased 
using image fusion software, which combines the spectra from the MALDI with an image taken 
from a histological stain (acquired with a light microscope) and relates these images to predict, 
with greater resolution, where the analyte is located.59  
Closing Remarks 
Metabolic assays such as liver microsome stability and brain homogenate metabolism give us 
an indication of about the in vivo stability of a drug, which enables early stage rule-outs for 
some drug candidates. This is no trivial task, as medicinal chemists typically synthesize dozens if 
not hundreds of analogs around a particular lead compound, and high throughput screening 
methods are necessary to hone in on the most viable drug candidates. In vitro assays enable us 
to choose the best lead compounds to move forward with in vivo studies. Pharmacokinetic 
studies are not high throughput assays, rather they are time consuming and expensive. 
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However, these assays are paramount to gather more information about ADME and 
formulation. Absolute compound quantitation verifies the presence or absence within real 
biological samples. Low limits of detection were achieved using a triple quad LC-MS/MS at 
UWM. Without the low limits of detection offered by LC-MS/MS analysis, later time points of a 
PK study would be challenging to quantify, which would make the calculation of PK parameter 
such as clearance more difficult. Prior to the development of these methods researchers at 
UWM were forced to hire an outside CRO for these studies (contract research organization). 
Based on this analysis, we were able to show by MALDI IMS where within that target tissue a 
compound was located. MALDI-IMS is an exciting field in mass spectrometry with new 
applications still emerging.  
In the future, MIDD investigators can combine pharmacokinetics studies and mass 
spectrometry imaging. We have not yet attempted this method, and it is actually a 
controversial approach as MALDI is generally thought to be a semi-quantitative method. 
Without standards, quantification based on desorption and ionization is not reliable. In 
addition, complex matrix effects seen with in vivo samples, such as tissue slice thickness, 
further complicate the separation of ions and the ability to quantify. Other research groups are 
attempting to tackle this issue by using different internal and external standard methods.53, 60 
This is an interesting potential future direction because it would offer the ability to combine 
two experiments into one, quantifying the amount of compound in the tissue and also showing 
the localization of this compound at the same time.  
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Another important future direction for the MIDD lies in high resolution mass spectrometry and 
its application in metabolomics. IT-TOF provides high resolution capabilities in LC-MS/MS, and 
compounds can be fragmented multiple times to elucidate structures. Our current approach 
creates metabolites in vitro, with the microsome assay, and in vivo, with PK studies. One 
particular metabolite, XHE-III-74 acid, has been shown specificity for the alpha 4 GABAAR 
subunit and is generated in vivo from the precursor, XHE-III-74 ethyl ester. This metabolite was 
discovered using a unit resolution quadrupole instrument, which is less ideal for metabolomics. 
However, the IT-TOF possesses formula prediction software in addition to the MSn 
fragmentation capabilities. Therefore it is the ideal instrument to continue investigation of both 
active and non-active metabolites. In addition, once robust methods for metabolite 
identification are established, excretion samples could be collected and investigated. Phase II 
metabolites would be of high interest here. Blood or other tissue samples could be further 
investigated to look for pro-drug possibilities. HRMS is an incredible tool for metabolite 
identification and we are mere steps away from exploring this field within the Arnold Group 
embedded in the MIDD.  
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Quantification of low molecular weight compounds by MALDI imaging mass spectrometry - A tutorial 
review. Biochimica et biophysica acta 2017, 1865 (7), 726-739. 
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Appendix A: MRM parameters for α5β3γ2 selective ligands 
 
Compound 
Name 
Precursor 
m/z 
Product 
m/z 
Dwell 
time 
Q1 pre 
bias (V) 
Collision 
Energy 
Q3 Pre 
Bias (V) Structure 
MP II 069 383.20 339.20 20.0 -13.0 -13.0 -21.0   
  
 
329.30 20.0 -23.0 -16.0 -30.0   
    311.20 20.0 -24.0 -22.0 -10.0   
MP II 068 371.20 329.00 20.0 -23 -15 -21   
  
 
311.00 20.0 -23 -23.0 -30.0   
  
 
285.10 20.0 -23 -21.0 -30.0   
    232.10 20.0 -23 -29 -23   
HZ 166 356.90 311.15 35.0 -17 -20 -30   
  
 
283.15 35.0 -17 -31 -18   
    282.15 35.0 -17 -39 -28   
MP III 024 343.20 311.00 20.0 -21 -20 -30   
  
 
283.00 20.0 -22 -30 -12   
    256.00 20.0 -17 -37 -26   
Diazepam 285.20 241.00 30.0 -18 -37 -22   
  
 
222.10 30.0 -19 -27 -22   
  
 
193.10 30.0 -19 -33 -29   
    154.10 30.0 -18 -27 -25   
MP III 004 373.95 342.05 30.0 -25 -18 -22   
  
 
314.25 30.0 -25 -30 -29   
  
 
273.00 30.0 -25 -40 -26   
MP IV 004 397.9 340.10 100.0 -26 -23 -36   
  
 
356.85 100.0 -26 -9 -40   
    220.70 100.0 -26 -30 -34   
MP024 HZ acid 328.9 297.05 30.0 -22 -8 -30   
  
 
99.10 30.0 -22 -21 -21   
    265.00 30.0 -22 -7 -28   
SH-053 2'F 373.9 327.95 30.0 -18 -20 -30   
  
 
299.95 30.0 -18 -34 -29   
    273.05 30.0 -18 -40 -27   
MP IV 062 267.95 240.10 30.0 -29 -11 -24   
  
 
144.05 30.0 -29 -20 -28   
    123.05 30.0 -29 -24 -20   
SH053 RS CH3 388 342.05 100.0 -19 -20 -21   
  
 
249.10 30.0 -19 -35 -20   
  
 
315.00 30.0 -19 -35 -20   
    301.00 100.0 -19 -30 -19   
Nordiazepam 276.05 213.00 10.0 -19 -30 -22   
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139.95 10.0 -19 -30 -22   
    164.90 10.0 -19 -35 -22   
GL-II-93 413.9 396 100 -20 -18 -24   
  
 
368 100 -30 -35 -20   
  
 
355.05 100 -30 -29 -36   
  
 
302.95 100 -28 -30 -32   
  
 
326.8 100 -30 -44 -32   
  
 
276.05 100 -30 -34 -28   
  
 
248.2 100 -30 -41 -26   
    168.1 100 -38 -43 -28   
SH-053 2'F R/S 
CH3 360 342.1 100 -24 -16 -22 
  
Acid 
 
316 100 -24 -17 -34   
  
 
301.1 100 -24 -29 -30   
  
 
249.05 100 -24 -28 -26   
    219.9 100 -24 -41 -40   
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Appendix B: MRM parameters for α4β3γ2 selective ligands 
Compound Name 
Precursor 
m/z 
Product 
m/z 
Dwell 
time 
Q1 pre 
bias (V) 
Collision 
Energy 
Q3 Pre 
Bias (V) Structure 
Xhe III 74 EE 342.00 296.15 30.0 -16.0 -19.0 -30.0   
  
 
278.15 
  
-28.0 -29.0   
    268.15     -31.0 -28.0   
Xhe III 74 Acid 313.90 296.05 100.0 -23 -16 -30   
  
 
278.00 100.0 -23 -26 -28   
  
 
108.95 100.0 -23 -40 -25   
                
Xhe III 74 (TBE) 370.00 338.45 35.0 -18 -9 -15   
  
 
314.20 35.0 -18 -13 -20   
  
 
296.15 35.0 -18 -22 -30   
    149.30 30.0 -17 -30 -20   
MRS-01-64 326.8 100.4 100 -36 -38 -40   
  
 
296 100 -36 -19 -30   
  
 
278.1 100 -38 -27 -28   
  
 
268.2 100 -36 -29 -26   
  
 
227.1 100 -36 -36 -40   
    247.1 100 -36 -38 -22   
MRS-01-67 357.7 296.2 30 -17 -15 -30   
  
 
278.2 30 -17 -27 -29   
    290.4 30 -17 -32 -21   
MRS-01-36 355.7 296.15 30 -17 -21 -30   
  
 
216.5 30 -17 -35 -12   
    120.8 30 -17 -30 -18   
CMD-45 356 300.15 35 -17 -11 -30   
  
 
282.1 35 -17 -22 -28   
    227.4 35 -17 -40 -15   
MRS-01-66 340.85 296.05 100 -40 -20 -30   
  
 
277.95 100 -40 -20 -30   
  
 
268.1 100 -40 -20 -30   
    227.15 100 -40 -20 -30   
RJ-02-50 328.05 282.05 100 -16 -20 -18   
  
 
192.9 100 -16 -19 -25   
    264.1 100 -16 -30 -16   
Xhe Acid OCD3 316.9 299.05 100 -20 -16 -20   
  
 
281 100 -20 -26 -20   
    111.95 100 -20 -40 -20   
Xhe EE OCD3 345.05 298.55 100 -22 -18 -28   
RJ-02-46 
 
281.15 100 -22 -28 -28   
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    271.15 100 -22 -31 -26   
Xhe TBE OCD3 299.15 299.15 100 -24 -22 -30   
RJ-02-52 281.1 281.1 100 -20 -34 -28   
  271.1 271.1 100 -20 -36 -26   
MRS 01 68 328 296.1 100 -22 -18 -30   
  328 277.95 100 -36 -29 -28   
  328 268.05 100 -36 -31 -26   
  328 250.95 100 -36 -37 -40   
  328 227.1 100 -36 -36 -36   
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Appendix C: MRMs for non-benzodiazepine compounds 
Compound Name 
Precursor 
m/z 
Product 
m/z 
Dwell 
time 
Q1 pre 
bias (V) 
Collision 
Energy 
Q3 Pre 
Bias (V) Structure 
GABA 104.10 87.10 100.0 -22.0 -15.0 -26.0   
  
 
86.10 100.0 -22.0 -15.0 -28.0   
    69.20 100.0 -22.0 -10.0 -26.0   
4,6-diphenyl N OH pyridone 264 218.15 30 -30 -22 -21   
  
 
247.05 30 -13 -21 -14   
  
 
218.95 30 -19 -31 -21   
pBBG 614 416.80 30 -32 -19 -27   
  
 
331.90 30 -32 -26 -21   
  
 
245.90 30 -32 -34 -24   
    170.80 30 -32 -48 -27   
pBBG Diacid 477.95 170.95 30 -34 -37 -30   
  
 
348.95 30 -34 -15 -38   
    332.00 30 -34 -18 -34   
Verapamil 454.7 165.15 100 -22 -30 -28   
  
 
150.20 100 -22 -29 -30   
    303.30 100 -22 -43 -26   
MeGFN 
 
302.9 271.05 100 19 15 27   
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